Research activity information

• Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.
  Shiro Watanabe; Kenji Hirata; Junki Takenaka; Yamato Munakata; Keiichi Magota; Naoto Wakabayashi; Hiroto Koga; Kohsuke Kudo
  Annals of nuclear medicine, 23 Jan. 2026, [Domestic magazines]
  English, Scientific journal
• Spinal decompression and radionuclide therapy for an unresectable FGF23 transmitted tumor causing cervical myelopathy: a case report and literature review.
  Shin Yokoyama; Hirokazu Shimizu; Akiko Yuno; Junki Takenaka; Naoto Wakabayashi; Shiro Watanabe; Ken Kuwahara; Masatake Matsuoka; Tomohiro Onodera; Norimasa Iwasaki; Akira Iwata
  Frontiers in oncology, 16, 1754565, 1754565, 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Tumor-induced osteomalacia (TIO) is a rare disorder characterized by hypophosphatemic osteomalacia, mainly caused by benign tumors with excessive secretion of fibroblast growth factor 23 (FGF23) and somatostatin receptor expression. Although complete excision is recommended, reports on treatment strategies for anatomically challenging surgical cases are lacking. We report an unresectable case of FGF23 transmitted tumor in the cervical vertebrae causing myelopathy, which was treated with surgical decompression combined with radionuclide therapy. CASE PRESENTATION: A 52-year-old woman presented to another hospital with complaints of knee pain. After confirming abnormal tracer uptake at the C7 vertebrae using somatostatin receptor scintigraphy and an elevated serum FGF23 level (>800 pg/mL), TIO was diagnosed 7 years after the initial presentation. Gait disturbance occurred 10 years after the initial presentation; therefore, the patient was referred to our department. Magnetic resonance imaging revealed a tumor with spinal cord compression and vertebral artery encasement, making complete resection impossible. Gait disturbance improved after spinal decompression with partial resection of the tumor. Peptide receptor radionuclide therapy targeting somatostatin receptors was initiated 2 years after surgery. Serum phosphate levels normalized, and the tumor size remained stable after the initiation of PRRT. Ambulation was maintained without joint pain recurrence at 3 years after surgery. CONCLUSIONS: The current literature on FGF23 transmitted tumors in the cervical spine includes six cases treated with definitive local therapy. This case suggests an alternative option for unresectable FGF23 transmitted tumor in the vertebrae, causing spinal myelopathy.
• Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis.
  Yuriko Ishida; Shiro Watanabe; Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Hajime Kikuchi; Yasutaka Kawai; Hirokazu Kimura; Sho Nakakubo; Kenji Hirata; Kohsuke Kudo; Satoshi Konno
  Japanese journal of radiology, 44, 1, 147, 155, Jan. 2026, [Domestic magazines]
  English, Scientific journal, PURPOSE: Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose (FDG) accumulation in IP with lung cancer complicated with IP and the incidence of AE. This study investigates the association between FDG accumulation in the interstitial lesions and the AE incidence in patients with lung cancer complicated with IP. MATERIALS AND METHODS: This multicenter, retrospective study included patients with lung cancer complicated with IP who received chemotherapy. All CTs at baseline and the onset of AE were centrally adjudicated. The SUVpeak and FDGscore for interstitial lesions were calculated from FDG positron emission tomography images before chemotherapy, and these values were corrected using reference uptake. To determine the association with AE risk, clinical characteristics and imaging findings were compared between patients who developed AE and those who did not. Subsequently, logistic regression analysis was performed to identify risk factors for the development of AE. RESULTS: One hundred and thirteen patients who met the eligibility criteria were enrolled from three centers. However, 9 patients with a clinical diagnosis of collagen-related interstitial pneumonia were excluded due to predominant FDG accumulation in the interstitial lesions, and 104 patients were analyzed. Of those patients, 31.7% (33/104) developed all grade AE and 18.3% (19/104) developed grade 3 or higher. There were no significant differences in patient characteristics and imaging patterns between those with and without AE. SUVpeak in the ipsilateral and contralateral interstitial lesions to the tumor and the FDGscore did not differ between those with or without AE. CONCLUSIONS: No association was observed between FDG accumulation in interstitial lesions and AE in patients with lung cancer complicated with IP. We may have to remain cautious about the risk of AE in lung cancer complicated with IP, even when FDG accumulation in interstitial lesions is high or low.
• Evaluation of artificial-intelligence-based liver segmentation and its application for longitudinal liver volume measurement.
  Rina Kimura; Kenji Hirata; Satonori Tsuneta; Junki Takenaka; Shiro Watanabe; Daisuke Abo; Kohsuke Kudo
  Abdominal radiology (New York), 50, 12, 6192, 6200, Dec. 2025, [International Magazine]
  English, Scientific journal, BACKGROUND: Accurate liver-volume measurements from CT scans are essential for treatment planning, particularly in liver resection cases, to avoid postoperative liver failure. However, manual segmentation is time-consuming and prone to variability. Advancements in artificial intelligence (AI), specifically convolutional neural networks, have enhanced liver segmentation accuracy. We aimed to identify optimal CT phases for AI-based liver volume estimation and apply the model to track liver volume changes over time. We also evaluated temporal changes in liver volume in participants without liver disease. METHODS: In this retrospective, single-center study, we assessed the performance of an open-source AI-based liver segmentation model previously reported, using non-contrast and dynamic CT phases. The accuracy of the model was compared with that of expert radiologists. The Dice similarity coefficient (DSC) was calculated across various CT phases, including arterial, portal venous, and non-contrast, to validate the model. The model was then applied to a longitudinal study involving 39 patients without liver disease (527 CT scans) to examine age-related liver volume changes over 5 to 20 years. RESULTS: The model demonstrated high accuracy across all phases compared to manual segmentation. Among the CT phases, the highest DSC of 0.988 ± 0.010 was in the arterial phase. The intraclass correlation coefficients for liver volume were also high, exceeding 0.9 for contrast-enhanced phases and 0.8 for non-contrast CT. In the longitudinal study, the model indicated an annual decrease of 0.95%. CONCLUSION: This model provides high accuracy in liver segmentation across various CT phases and offers insights into age-related liver volume reduction. Measuring changes in liver volume may help with the early detection of diseases and the understanding of pathophysiology.
• Unexpected [18F] Fluciclovine Uptake in Pilocytic Astrocytoma: A Pediatric Case Report.
  Hiroto Koga; Shiro Watanabe; Kenji Hirata; Yukitomo Ishi; Shigeru Yamaguchi; Kohsuke Kudo
  Clinical nuclear medicine, 20 Nov. 2025, [International Magazine]
  English, Scientific journal, A 5-year-old asymptomatic boy underwent MRI, which revealed a mass lesion in the septum pellucidum suspected to be a glioma. [18F]Fluciclovine PET, which provides insight into amino acid metabolism, revealed high uptake (SUVmax, 2.37; TBR, 3.56), which was consistent with high-grade glioma. In contrast, [18F] Fluorodeoxyglucose PET showed low uptake (SUV max: 2.2; TBR: 0.29). Partial resection and histopathology confirmed pilocytic astrocytoma, a WHO grade 1 tumor, with KIAA1549-BRAF fusion. High [18F] Fluciclovine uptake in pilocytic astrocytoma may reflect amino acid transporter expression, which may lead to overestimation of the WHO grade. Awareness of this pitfall is essential in pediatric neuro-oncology.
• Fluciclovine-PET Uptake in Microcystic Meningioma Mimicking High-grade Glioma: A Case Report.
  Junki Takenaka; Kenji Hirata; Shiro Watanabe; Yukitomo Ishi; Kohsuke Kudo
  Clinical nuclear medicine, 50, 10, 975, 977, 01 Oct. 2025, [International Magazine]
  English, Scientific journal, A 69-year-old asymptomatic woman underwent magnetic resonance imaging (MRI), revealing a left parietal lobe tumor suspected to be a high-grade glioma (HGG). [ 18 F]Fluciclovine-positron emission tomography (PET), which reflects amino acid metabolism, showed moderate uptake [SUVmax 1.4, tumor-to-normal ratio (TNR) 1.9], consistent with HGG, whereas [ 18 F]fluorodeoxyglucose-PET findings demonstrated low uptake (SUVmax 2.5, TNR 0.22), which is atypical for HGG. Surgical and pathologic investigations confirmed the diagnosis of microcystic meningioma, a rare subtype classified as grade 1. Microcystic meningiomas mimic HGG on magnetic resonance imaging and [ 18 F]fluciclovine-PET due to l -amino acid transporter expression, complicating diagnosis.
• The Biochemical-Imaging Connection: Urinary Noradrenaline and Fluorodeoxyglucose-Positron Emission Tomography in Unresectable or Metastatic Pheochromocytomas and Paragangliomas.
  Junki Takenaka; Shiro Watanabe; Takashige Abe; Satoshi Takeuchi; Kenji Hirata; Rina Kimura; Hiroshi Ishii; Naoto Wakabayashi; Mungunkhuyag Majigsuren; Kohsuke Kudo
  Diagnostics (Basel, Switzerland), 15, 11, 22 May 2025, [International Magazine]
  English, Scientific journal, Background/Objectives: Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of neural crest origin that secrete varying levels of catecholamines. [18F]Fluorodeoxyglucose-positron emission tomography (FDG-PET) is a valuable tool for the detection of metastases and the prediction of prognoses. However, varying FDG avidities in PPGLs raise concerns regarding cost-effectiveness and unnecessary radiation exposure. Catecholamine secretion patterns are associated with metastasis and clinical outcomes. This study aimed to explore the relationships among FDG avidity, catecholamine levels, and clinical factors in patients with PPGLs. Methods: This retrospective study included 25 patients with unresectable or metastatic PPGLs scheduled for [131I]metaiodobenzylguanidine therapy with FDG-PET data available within 40 days of urine catecholamine measurements. FDG avidity was assessed using semiquantitative parameters such as the maximum standardized uptake value (SUVmax), total metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Urine catecholamine levels were quantified. Logistic regression and Spearman's correlation were performed to evaluate the relationship between FDG parameters and urinary catecholamine levels. Results: Urinary noradrenaline levels were significantly higher in patients with FDG-avid lesions than in those without (726.25 μg/day vs. 166.3 μg/day, p = 0.001). Noradrenaline levels showed significant positive correlations with SUVmax, MTV, and TLG (ρ = 0.527, 0.541, and 0.557, respectively; all p < 0.01). Urinary noradrenaline levels predicted FDG avidity with an AUC of 0.849; a cutoff value of 647.5 μg/day achieved 55.6% sensitivity and 100% specificity. Conclusions: Urinary noradrenaline levels were significantly associated with FDG avidity in PPGLs, suggesting their potential utility in predicting FDG-PET outcomes. Therefore, FDG-PET may be unnecessary in PPGL patients with low urinary noradrenaline levels. These findings may help optimize imaging strategies for patients with PPGLs.
• Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors.
  Naoto Wakabayashi; Shiro Watanabe; Satoshi Takeuchi; Takahiro Tsuchikawa; Yamato Munakata; Kenji Hirata; Rina Kimura; Junki Takenaka; Hiroshi Ishii; Kohsuke Kudo
  Annals of nuclear medicine, 05 Apr. 2025, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: In peptide receptor radionuclide therapy (PRRT) using lutetium-177-labeled DOTA-Tyr3-octreotate ([177Lu] DOTATATE), isolation is required until the external dose rate at 1 m (EDR-1 m) from the body surface falls below the regulatory standards of each country. While it is known that renal function influences EDR-1 m reduction within 180 min post-administration, the factors affecting EDR-1 m on the day following administration (Late EDR-1 m) remain unclear. This study aimed to identify factors influencing Late EDR-1 m after PRRT using [177Lu] DOTATATE for neuroendocrine tumors and to predict Late EDR-1 m using pretreatment [111In] pentetreotide single-photon emission computed tomography/computed tomography (SPECT/CT) data. METHODS: This study analyzed 111 PRRT cycles administered to 36 patients between September 2021 and August 2024. Late EDR-1 m was set as the dependent variable, whereas total radiopharmaceutical uptake (LUTtotal), dose per body weight, creatinine clearance (CCr), and albumin-bilirubin (ALBI) score were set as the independent variables in the multiple regression analysis. LUTtotal was calculated using SPECT/CT data acquired after the patient left the radiation therapy room, defining the volume of interest (VOI) as the area with SUVmean + 2SD or higher in the skeletal muscle. The VOI volume multiplied by the SUVmean was used to define LUTtotal. In addition, using [111In] pentetreotide SPECT/CT data, the total radiopharmaceutical uptake (OCTtotal) was calculated in a manner similar to LUTtotal, and its correlation with LUTtotal was examined. A predictive equation for Late EDR-1 m was developed using the results of the multivariate analysis, and its performance was tested using subsequent cases between August 2024 and January 2025. RESULTS: The median measured Late EDR-1 m was 8.0 (range, 4.0-26.0) μSv/h. LUTtotal and dose per body weight were significantly correlated with Late EDR-1 m, whereas CCr and ALBI scores were not. Based on the results of the multivariate analysis, the predictive equation using the dose per body weight, assuming a dosage of 7400 MBq and OCTtotal, achieved a root mean square error (RMSE) of 2.24 μSv/h. In subsequent test cases, the RMSE was 3.47 μSv/h. CONCLUSIONS: Late EDR-1 m is significantly correlated with LUTtotal and dose per body weight. It can be accurately predicted using [111In] pentetreotide SPECT/CT data.
• 18F-FDG PET/CT読影レポート生成システム構築に向けたプロンプト技術の検討
  南 和孝; 吉村 高明; 平田 健司; 甲木 晶枝; 植竹 望; 渡邊 史郎; 工藤 與亮
  日本放射線技術学会総会学術大会予稿集, 81回, 291, 291, (公社)日本放射線技術学会, Mar. 2025
  Japanese
• ChatGPTによる読影レポートからの情報抽出の初期検討
  土橋 大樹; 平田 健司; 渡邊 史郎; 竹中 淳規; 若林 直人; 木村 理奈; 工藤 與亮; 土橋 大樹; 木村 理奈; 工藤 與亮; 平田 健司; 渡邊 史郎; 竹中 淳規; 若林 直人
  Japanese Journal of Radiology, 43, Suppl., 6, 6, (公社)日本医学放射線学会, Feb. 2025
  Japanese
• Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [131I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study
  Junki Takenaka; Shiro Watanabe; Takashige Abe; Satoshi Takeuchi; Kenji Hirata; Rina Kimura; Hiroshi Ishii; Naoto Wakabayashi; Mungunkhuyag Majigsuren; Kohsuke Kudo
  Pharmaceuticals, 18, 2, 165, 165, MDPI AG, 26 Jan. 2025
  Scientific journal, Background/Objectives: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that produce catecholamines. Unresectable or metastatic PPGLs are treated with [131I]metaiodobenzylguanidine (MIBG), but MIBG avidity is often heterogeneous. Identifying predictive factors for non-avid lesions on scintigraphy is clinically important. The primary objective of this study was to investigate the relationship between MIBG avidity and catecholamine secretion patterns in patients with unresectable or metastatic PPGLs. Methods: This retrospective study included 27 patients treated with [131I]MIBG for unresectable/metastatic PPGLs between 2001 and 2024. Patients received a single intravenous dose of [131I]MIBG (5.5–7.4 GBq), with post-therapy scintigraphy performed 3–7 days later. Non-avid lesions were assessed by imaging and confirmed using CT, MRI, and FDG-PET. Clinical factors, including age, sex, prior treatments, metastasis sites, and urine catecholamines, were evaluated using univariate logistic analysis. Predictive factors were assessed via receiver operating characteristic curves. Results: Non-avid lesions were found in nine patients (33.3%). These patients were younger (median age 38 vs. 62.5 years) and had higher urine dopamine levels (median 1510 vs. 779 μg/day) than those without non-avid lesions. Younger age (odds ratio: 0.892, p < 0.01) and higher urinary dopamine levels (odds ratio: 1.003, p < 0.01) were significantly associated with non-avid lesions. All patients > 45 years with urinary dopamine < 1190 μg/day had no non-avid lesions, whereas patients < 45 years with urinary dopamine > 1190 μg/day had non-avid lesions. Conclusions: Age and urinary dopamine levels may predict non-avid lesions in unresectable/metastatic PPGLs, aiding treatment decisions for [131I]MIBG therapy. This article is a revised and expanded version of a paper entitled “Urine dopamine level and age can predict non-avid lesion on scintigraphy after I-131 MIBG treatment for unresectable/metastatic PPGL”, which was presented at SNMMI 2024, Toronto, from 8 June to 11 June 2024.
• Correction: Maximum standardized uptake value in 11C-methionine positron emission tomography may predict the prognosis of patients with oral squamous cell carcinoma.
  Takeshi Kuroshima; Yoshimasa Kitagawa; Jun Sato; Shiro Watanabe; Takuya Asaka; Takahiro Abe; Hiroyuki Harada; Kenji Hirata; Yuji Kuge
  Odontology, 113, 1, 379, 379, Jan. 2025, [Domestic magazines]
  English
• Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy.
  Leo Hashimoto; Shiro Watanabe; Mungunkhuyag Majigsuren; Kenji Hirata; Junki Takenaka; Rina Kimura; Hiroshi Ishii; Kohsuke Kudo
  Asia Oceania journal of nuclear medicine & biology, 13, 2, 208, 212, 2025, [International Magazine]
  English, Scientific journal, Brain metastasis (BM) occurs only in about 1% of differentiated thyroid carcinoma (DTC) cases. Although DTC generally has a good prognosis, once BM develops, the mortality rate significantly increases up to 78%. BM is usually treated by surgical resection or external radiotherapy, whereas radioactive iodine therapy (RAIT) using I-131 is much less often chosen because BM often shows poor uptake of I-131. In addition, even in case I-131 accumulates in the BM, RAIT could cause adverse effects such as brain hemorrhage and cerebral edema. We present a case of BM from DTC that showed response to I-131 therapy with no severe adverse effects. The brain lesion was very small and asymptomatic, and was only found after a post-therapy I-131 scintigraphy. There are a few case reports where BM was cured by RAIT with little to no side effects. We theorize that BM that is small in size, asymptomatic and show I-131 accumulation could be successfully treated with RAIT.
• Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis.
  Naoto Wakabayashi; Shiro Watanabe; Takashige Abe; Junki Takenaka; Kenji Hirata; Rina Kimura; Keita Sakamoto; Nobuo Shinohara; Kohsuke Kudo
  Annals of nuclear medicine, 38, 7, 553, 562, Jul. 2024, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs). METHODS: A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5.55 GBq) of I-131 MIBG. We evaluated the first MIBG treatment and repeated MIBG treatments performed within 200 days of the previous treatment. AEs for each treatment were evaluated using CTCAE version 4.0, and the statistical analysis was conducted at a significance level of p < 0.05. Objective response based on RECIST 1.1 criteria and biochemical response based on urinary catecholamines were assessed. RESULTS: The study included a total of 63 administrations, consisting of 28 single administrations (SAs), including the first administration for all 28 cases, and 35 multiple administrations (MAs), which included the second or later administrations. Hematological AEs were evaluable for 23 SAs and 29 MAs. Grade 3 or higher leukopenia occurred in 9.8% of all administrations, and Grade 3 or higher lymphopenia in 23.5%; both were manageable through observation. There were no significant differences in clinical AE Grades 1-2 (p = 0.32), hematological AE Grades 1-2 (p = 0.22), or hematological AE Grades 3-4 (p = 0.12) between MAs and SAs. Statistical analysis for each type of AE revealed significant increases in leukopenia (p < 0.01) and lymphopenia (p = 0.04). No significant difference in anemia, thrombocytopenia, or neutropenia was observed between MAs and SAs. There was no significant increase in the incidence rate of Grade 3 or higher hematological AEs for any of the parameters. The objective response rate was 0% for SAs and 36% for MAs. Biochemical response rates were 18% for SAs and 67% for MAs. CONCLUSION: In I-131 MIBG therapy for PPGLs, multiple administrations significantly increased only Grade 1 or 2 lymphopenia and leukopenia compared to single administration.
• 血液維持透析患者の甲状腺癌に対して放射性ヨウ素内用療法を施行した1例
  江口 みな; 上田 雄翔; 中沢 大悟; 西尾 妙織; 竹中 淳規; 渡邊 史郎; 平田 健司; 村田 裕宣; 千葉 裕基; 武貞 敬介; 篠原 信雄
  日本透析医学会雑誌, 57, Suppl.1, 479, 479, (一社)日本透析医学会, May 2024
  Japanese
• Maximum standardized uptake value in 11C-methionine positron emission tomography may predict the prognosis of patients with oral squamous cell carcinoma
  Kuroshima T; Kitagawa Y; Sato J; Watanabe S; Asaka T; Abe T; Harada H; Hirata K; Kuge Y
  Odontologgy, PMID: 38703257, May 2024, [Peer-reviewed]
• 腫瘍性骨軟化症における111Inペンテトレオチドを用いたソマトスタチン受容体シンチグラフィにてSPECT-CTが有用であった一例
  平野 佑亮; 宗像 大和; 前田 佑介; 平田 健司; 渡邊 史郎; 竹中 淳規; 孫田 惠一
  北海道放射線技術雑誌, 96, 64, 65, (公社)日本放射線技術学会-北海道支部, Apr. 2024
  Japanese
• 切除不能/転移性PPGLにおけるI-131 MIBG治療後シンチグラフィーで非集積病変を有する患者の予測因子に関する検討
  竹中 淳規; 渡邊 史郎; 安部 崇重; 土川 貴裕; 竹内 啓; 平田 健司; 木村 理奈; 若林 直人; 篠原 信雄; 工藤 與亮
  日本内分泌外科学会雑誌, 41, Suppl.1, S202, S202, (一社)日本内分泌外科学会, Apr. 2024
  Japanese
• 大規模言語モデルを用いた読影レポートからの情報抽出 ChatGPT3.5、ChatGPT4およびGoogle Bardの比較
  土橋 大樹; 平田 健司; 渡邊 史郎; 竹中 淳規; 若林 直人; 木村 理奈; 坂本 圭太; 工藤 與亮
  北海道放射線医学雑誌, 4, 7, 12, (NPO)メディカルイメージラボ, Mar. 2024
  Japanese
• Accumulation of Technetium-99m Tetrofosmin on Myocardial Perfusion Scintigraphy in a Patient With Immunoglobulin G4-Related Coronary Periarteritis
  Satonori Tsuneta; Kenichiro Suno; Yuichiro Fujieda; Masaya Watanabe; Shiro Watanabe; Kenji Hirata; Toshiyuki Nagai; Kohsuke Kudo
  Canadian Journal of Cardiology, Mar. 2024, [Peer-reviewed]
  English, Scientific journal
• Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例
  北川 悠; 竹中 淳規; 渡邊 史郎; 平田 健司; 内山 裕子; 木村 理奈; 中川 純一; 池辺 洋平; 工藤 與亮; 長谷河 昌孝; 澤井 彩織; 寺下 友佳代; 杉山 未奈子; 平林 真介; 長 祐子; 真部 淳
  Japanese Journal of Radiology, 42, Suppl., 5, 5, (公社)日本医学放射線学会, Feb. 2024
  Japanese
• 神経内分泌腫瘍に対するLu-177 DOTATATE治療における投与翌日の体外線量率に影響を与える因子に関する検討
  若林 直人; 渡邊 史郎; 竹内 啓; 土川 貴裕; 平田 健司; 木村 理奈; 竹中 淳規; 石井 宙史; 南部 敏和; 工藤 與亮
  核医学, 61, Suppl., S157, S157, (一社)日本核医学会, 2024
  Japanese
• 切除不能/転移性PPGLにおけるMIBG治療前のFDG-PETの集積性に関する検討
  竹中 淳規; 渡邊 史郎; 安部 崇重; 土川 貴裕; 竹内 啓; 平田 健司; 木村 理奈; 石井 宙史; 若林 直人; 工藤 與亮
  核医学, 61, Suppl., S169, S169, (一社)日本核医学会, 2024
  Japanese
• 再発・転移を有する分化型甲状腺癌におけるソマトスタチンレセプター発現に関する検討
  渡邊 史郎; 平田 健司; 竹中 淳規; 石井 宙史; 若林 直人; 宗像 大和; 孫田 惠一; 工藤 與亮
  核医学, 61, Suppl., S176, S176, (一社)日本核医学会, 2024
  Japanese
• SurfaceMIP:FDG-PETで皮膚を観察するためのアルゴリズムの実装とパラメーター最適化
  平田 健司; 木村 理奈; 唐 明輝; 渡邊 史郎; 竹中 淳規; 石井 宙史; 杉森 博行; 吉村 高明; 工藤 與亮
  核医学, 61, Suppl., S162, S162, (一社)日本核医学会, 2024
  Japanese
• 2.5次元DDSRCNNを用いた低カウントPET画像の画質改善モデルの開発と定量性評価
  遠藤 大輝; 吉村 高明; 唐 明輝; 杉森 博行; 孫田 惠一; 木村 理奈; 渡邊 史郎; 平田 健司; 工藤 與亮
  核医学, 61, Suppl., S188, S188, (一社)日本核医学会, 2024
  Japanese
• 神経内分泌腫瘍に対するLu-177 DOTATATE治療における投与翌日の体外線量率に影響を与える因子に関する検討
  若林 直人; 渡邊 史郎; 竹内 啓; 土川 貴裕; 平田 健司; 木村 理奈; 竹中 淳規; 石井 宙史; 南部 敏和; 工藤 與亮
  核医学, 61, Suppl., S157, S157, (一社)日本核医学会, 2024
  Japanese
• 切除不能/転移性PPGLにおけるMIBG治療前のFDG-PETの集積性に関する検討
  竹中 淳規; 渡邊 史郎; 安部 崇重; 土川 貴裕; 竹内 啓; 平田 健司; 木村 理奈; 石井 宙史; 若林 直人; 工藤 與亮
  核医学, 61, Suppl., S169, S169, (一社)日本核医学会, 2024
  Japanese
• 再発・転移を有する分化型甲状腺癌におけるソマトスタチンレセプター発現に関する検討
  渡邊 史郎; 平田 健司; 竹中 淳規; 石井 宙史; 若林 直人; 宗像 大和; 孫田 惠一; 工藤 與亮
  核医学, 61, Suppl., S176, S176, (一社)日本核医学会, 2024
  Japanese
• SurfaceMIP:FDG-PETで皮膚を観察するためのアルゴリズムの実装とパラメーター最適化
  平田 健司; 木村 理奈; 唐 明輝; 渡邊 史郎; 竹中 淳規; 石井 宙史; 杉森 博行; 吉村 高明; 工藤 與亮
  核医学, 61, Suppl., S162, S162, (一社)日本核医学会, 2024
  Japanese
• 2.5次元DDSRCNNを用いた低カウントPET画像の画質改善モデルの開発と定量性評価
  遠藤 大輝; 吉村 高明; 唐 明輝; 杉森 博行; 孫田 惠一; 木村 理奈; 渡邊 史郎; 平田 健司; 工藤 與亮
  核医学, 61, Suppl., S188, S188, (一社)日本核医学会, 2024
  Japanese
• Comparative study of physiological FDG uptake in small structures between silicon photomultiplier-based PET and conventional PET.
  Shiro Watanabe; Kenji Hirata; Keiichi Magota; Junki Takenaka; Naoto Wakabayashi; Daiki Shinyama; Koichi Yasuda; Akihiro Homma; Kohsuke Kudo
  Annals of nuclear medicine, 09 Nov. 2023, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: Silicon photomultiplier-based positron emission tomography/computed tomography (SiPM-PET/CT) has the superior spatial resolution to conventional PET/CT (cPET/CT). This head-to-head comparison study compared the images of physiological 18F-fluorodeoxyglucose (FDG) accumulation in small-volume structures between SiPM-PET/CT and cPET/CT in patients scanned with both modalities, and we investigated whether the thresholds that are reported to be useful for differentiating physiological accumulations from malignant lesions can also be applied to SiPM-PET/CT. METHODS: We enrolled 21 consecutive patients with head and neck malignancies who underwent whole-body FDG-PET/CT for initial staging or a follow-up evaluation (October 2020 to March 2022). After being injected with FDG, all patients underwent PET acquisition on both Vereos PET-CT and Gemini TF64 PET-CT systems (both Philips Healthcare) in random order. For each patient, the maximum standardized uptake value (SUVmax) was measured in the pituitary gland, esophagogastric junction (EGJ), adrenal glands, lumbar enlargement of the spinal cord, and epididymis. We measured the liver SUVmean and the blood pool SUVmean to calculate the target-to-liver ratio (TLR) and the target-to-blood ratio (TBR), respectively. Between-groups differences in each variable were examined by a paired t-test. We also investigated whether there were cases of target uptake greater than the reported threshold for distinguishing pathological from physiological accumulations. RESULTS: Data were available for 19 patients. Ten patients were in Group 1, i.e., the patients who underwent SiPM-PET first, and the remaining nine patients who underwent cPET first were in Group 2. In the SiPM-PET results, the SUVmax of all targets was significantly higher than that obtained by cPET in all patients, and this tendency was also observed when the patients were divided into Groups 1/2. The TLRs of all targets were significantly higher in SiPM-PET than in cPET in all patients, and SiPM-PET also showed significantly higher TBRs for all targets except the EGJ (p = 0.052). CONCLUSIONS: The physiological uptake in the small structures studied herein showed high accumulation on SiPM-PET. Our results also suggest that the thresholds reported for cPET to distinguish pathological accumulations likely lead to false-positive findings in SIPM-PET evaluations.
• 腫瘍性骨軟化症における111Inペンテトレオチドを用いたソマトスタチン受容体シンチグラフィにてSPECT-CTが有用であった一例
  平野 佑亮; 平田 健司; 渡邊 史郎; 竹中 淳規; 孫田 惠一; 宗像 大和; 前田 佑介
  北海道放射線技術雑誌, 95, 39, 39, (公社)日本放射線技術学会-北海道支部, Nov. 2023
  Japanese
• Bone Echinococcosis Mimicking Malignancy on FDG PET.
  Junki Takenaka; Kenji Hirata; Shiro Watanabe; Masahiko Takahata; Kohsuke Kudo
  Clinical nuclear medicine, 48, 11, e523-e525, 01 Nov. 2023, [International Magazine]
  English, Scientific journal, MRI revealed a thoracic vertebrae lesion in a 40-year-old woman with back pain. She was referred to our institution; MRI demonstrated a mass from the second to the fifth thoracic vertebra and compression fractures. CT revealed a splenic mass, multiple pulmonary nodules, and low-density masses in the liver. 18 F-FDG PET/CT showed increased uptake (SUV max , 10.6) in the peripheral rim of the thoracic vertebra mass, with central parts showing lower uptake than the peripheral rim. The splenic mass exhibited increased accumulation (SUV max , 4.8). The thoracic spine lesion was fixed; a biopsy was performed. Alveolar echinococcosis was confirmed immunologically. Alveolar echinococcosis can present with bone lesions. It must be differentiated from malignancy.
• Predictive factors of early FDG-PET response to [131I] MIBG treatment for unresectable or metastatic pheochromocytomas and paragangliomas (PPGLs).
  Junki Takenaka; Shiro Watanabe; Takashige Abe; Takahiro Tsuchikawa; Satoshi Takeuchi; Kenji Hirata; Rina Kimura; Naoto Wakabayashi; Nobuo Shinohara; Kohsuke Kudo
  Neuroendocrinology, 19 Sep. 2023, [International Magazine]
  English, Scientific journal, Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that produce catecholamines. [131I] MIBG-avid unresectable or metastatic PPGLs are treated with [131I] MIBG therapy. A high metabolic tumour volume (MTV) and total lesion glycolysis (TLG) can be poor prognostic factors. Therefore, we evaluated the metabolic responses to [131I] MIBG therapy with respect to other clinical factors.A retrospective study was performed on a series of 20 patients who underwent FDG-PET before and after [131I] MIBG therapy. We administered a single dose comprising 5.5 GBq of [131I] MIBG. Semi-quantitative parameters (SUVmax, MTV, and TLG) were calculated using the liver SUV (mean + 3SD) as a threshold on Metavol software. The semi-quantitative FDG-PET parameters for determining response were complete response , partial remission, stable disease, and progressive disease (PD). We divided our study participants into the PD and non-PD groups and compared the overall survival between the two groups. Subsequently, we evaluated the relationships between metabolic response and age, sex, tumour type, metastatic site, chemotherapy or external radiation history, and 24-hour urine catecholamine levels by univariate logistic regression analyses. Both MTV-based and TLG-based criteria for PD vs. non-PD were significant prognostic factors (p = 0.014). However, treatment response as evaluated based on the SUVmax was not a significant predictor. Higher urinary dopamine levels were associated with poor metabolic response as assessed by MTV and TLG. The other clinical parameters were non-significant. Poor metabolic response (measured with MTV and TLG) to [131I] MIBG therapy in unresectable or metastatic PPGLs was related to shorter OS. The poor metabolic response can be predicted using the urinary dopamine level.
• Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study.
  Satoshi Takeuchi; Kenji Hirata; Keiichi Magota; Shiro Watanabe; Rika Moku; Akihiko Shiiya; Jun Taguchi; Shin Ariga; Tomohiro Goda; Yoshihito Ohhara; Takurou Noguchi; Yasushi Shimizu; Ichiro Kinoshita; Rio Honma; Yasushi Tsuji; Akihiro Homma; Hirotoshi Dosaka-Akita
  EJNMMI research, 13, 1, 69, 69, 17 Jul. 2023, [International Magazine]
  English, Scientific journal, BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes. RESULTS: This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion. Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation. Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation. The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT. Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve. Twenty-one patients were included in this analysis. Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment. The best cut-off value for the treatment response for SUVmax was 15.211. The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively. The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value (P = 0.078). CONCLUSIONS: The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT. PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC. TRIAL REGISTRATION: This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016.
• Sunburst appearanceを呈する頭蓋骨腫瘤を契機に発見された神経芽腫の1例
  北川 悠; 竹中 淳規; 渡邊 史郎; 平田 健司; 内山 裕子; 木村 理奈; 中川 純一; 池辺 洋平; 長谷河 昌孝; 澤井 彩織; 寺下 友佳代; 杉山 未奈子; 平林 真介; 長 祐子; 山口 秀; 真部 淳; 工藤 與亮
  北海道放射線医学雑誌, 3, 33, 36, (NPO)メディカルイメージラボ, Mar. 2023
  Japanese
• 切除不能/転移性PPGLにおける初回I-131MIBG治療による総糖代謝量の変化と予後の関係性の解析
  竹中 淳規; 渡邊 史郎; 安部 崇重; 土川 貴裕; 竹内 啓; 平田 健司; 木村 理奈; 若林 直人; 篠原 信雄; 工藤 與亮
  核医学, 60, Suppl., S216, S216, (一社)日本核医学会, 2023
  Japanese
• 褐色細胞腫・傍神経節腫に対するI-131MIBG治療の単回投与と複数回投与での有害事象発生率の検討
  若林 直人; 渡邊 史郎; 安部 崇重; 竹中 淳規; 平田 健司; 篠原 信雄; 工藤 與亮
  核医学, 60, Suppl., S216, S216, (一社)日本核医学会, 2023
  Japanese
• MIP類似アルゴリズムによるFDG-PET体表画像の有用性
  平田 健司; 木村 理奈; 唐 明輝; 渡邊 史郎; 竹中 淳規; 若林 直人; 杉森 博行; 吉村 高明; 工藤 與亮
  核医学, 60, Suppl., S208, S208, (一社)日本核医学会, 2023
  Japanese
• SRCNNを用いた短時間収集PET画像の画質改善モデルの開発と定量性評価
  遠藤 大輝; 吉村 高明; 唐 明輝; 杉森 博行; 長谷川 淳; 小亀 翔揮; 孫田 惠一; 木村 理奈; 渡邊 史郎; 平田 健司; 工藤 與亮
  核医学, 60, Suppl., S209, S209, (一社)日本核医学会, 2023
  Japanese
• 切除不能/転移性PPGLにおける初回I-131MIBG治療による総糖代謝量の変化と予後の関係性の解析
  竹中 淳規; 渡邊 史郎; 安部 崇重; 土川 貴裕; 竹内 啓; 平田 健司; 木村 理奈; 若林 直人; 篠原 信雄; 工藤 與亮
  核医学, 60, Suppl., S216, S216, (一社)日本核医学会, 2023
  Japanese
• 褐色細胞腫・傍神経節腫に対するI-131MIBG治療の単回投与と複数回投与での有害事象発生率の検討
  若林 直人; 渡邊 史郎; 安部 崇重; 竹中 淳規; 平田 健司; 篠原 信雄; 工藤 與亮
  核医学, 60, Suppl., S216, S216, (一社)日本核医学会, 2023
  Japanese
• Neuroblastoma-related severe hypoperfusion in the cerebellum of an infant: A case of opsoclonus-myoclonus syndrome.
  Junki Takenaka; Kenji Hirata; Shiro Watanabe; Hideaki Shiraishi; Kohsuke Kudo
  Asia Oceania journal of nuclear medicine & biology, 11, 1, 93, 96, 2023, [International Magazine]
  English, A 2-year-old girl started to wobble without any specific triggers, so the patient was admitted to our hospital's pediatric department. The entire cerebellum showed severe atrophy on MRI and much lower uptake than that in the cerebral cortex on perfusion SPECT. The diagnosis of opsoclonus-myoclonus syndrome (OMS) was suspected. MRI visualized a small mass behind the inferior vena cava. Although its uptake on I-123 MIBG scintigraphy was inconclusive, the mass was surgically removed, and the diagnosis of neuroblastoma was pathologically confirmed. OMS is one of the paraneoplastic neurological syndromes with cerebellar ataxia, myoclonus of the trunk and extremities, and opsoclonus as its main symptoms. Approximately 50% of children cases with OMS are associated with neuroblastoma. The prognosis for neuroblastoma itself with OMS is relatively good, but the neurological prognosis is very poor. If there is decreased blood flow in the cerebellum of an infant, it may be necessary to search for neuroblastoma.
• MIP類似アルゴリズムによるFDG-PET体表画像の有用性
  平田 健司; 木村 理奈; 唐 明輝; 渡邊 史郎; 竹中 淳規; 若林 直人; 杉森 博行; 吉村 高明; 工藤 與亮
  核医学, 60, Suppl., S208, S208, (一社)日本核医学会, 2023
  Japanese
• SRCNNを用いた短時間収集PET画像の画質改善モデルの開発と定量性評価
  遠藤 大輝; 吉村 高明; 唐 明輝; 杉森 博行; 長谷川 淳; 小亀 翔揮; 孫田 惠一; 木村 理奈; 渡邊 史郎; 平田 健司; 工藤 與亮
  核医学, 60, Suppl., S209, S209, (一社)日本核医学会, 2023
  Japanese
• Estimation of Amyloid-β Positivity Using QSM Images Considering Age Information.
  Tsubasa Kunieda; Ren Togo; Noriko Nishioka; Yukie Shimizu; Shiro Watanabe; Kenji Hirata; Keisuke Maeda; Takahiro Ogawa 0001; Kohsuke Kudo; Miki Haseyama
  ICCE-Taiwan, 165, 166, 2023
  International conference proceedings
• Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL).
  Junki Takenaka; Shiro Watanabe; Takashige Abe; Kenji Hirata; Yuko Uchiyama; Rina Kimura; Nobuo Shinohara; Kohsuke Kudo
  Annals of nuclear medicine, 27 Oct. 2022, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: Pheochromocytomas and paragangliomas (PPGLs) are rare tumors arising from the neural crest cells that form the sympathetic and parasympathetic nervous systems. Radiotherapy with [131I]metaiodobenzylguanidine (MIBG) is recommended for unresectable PPGLs. We investigated the usefulness of the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting the prognosis of patients with unresectable PPGL(s) before receiving [131I]MIBG therapy. PATIENTS AND METHODS: We retrospectively analyzed the cases of 25 patients with unresectable PPGLs treated with [131I]MIBG at our hospital between 2001 and 2020. The MTV and TLG were measured in reference to liver accumulation. We divided the patients into two groups based on median values for the maximum standardized uptake value (SUVmax), MTV, and TLG, and evaluated between-group differences using log-rank tests. Cox proportional hazards models were used to determine whether there were significant differences in prognosis with respect to tumor type (pheochromocytoma vs. paraganglioma), site of metastasis, age, past treatment (chemotherapy, external radiation or [131I]MIBG treatment before the current [131I]MIBG treatment), urinary catecholamine, SUVmax, MTV, and TLG. RESULTS: The median follow-up time was 42 months (range 2-136 months). The median overall survival was 63 months. The overall survival (OS) was significantly shorter in the high-MTV group (log-rank test, p = 0.049) and the high-TLG group (p = 0.049), with no significant difference between the high- and low-SUVmax groups (p = 0.19). Likewise, there was no significant difference in prognosis according to pheochromocytoma or paraganglioma, metastasis location, age, or prior chemotherapy. A history of external radiation before [131I]MIBG treatment was associated with a significantly worse prognosis (hazard ration [HR] = 7.95, p = 0.0018). Urinary adrenaline and noradrenaline were not significant prognostic factors (p = 0.70, p = 0.25, respectively), but urinary dopamine did predict a worse outcome (p = 0.022). There was no increased risk of death for higher SUVmax or TLG (p = 0.63 and 0.057, respectively), but higher MTV did predict a worse outcome (HR = 7.27, p = 0.029). CONCLUSION: High MTV and high TLG were significantly associated with a poor prognosis after [131I]MIBG therapy for PPGLs. Other treatment strategies for such patients may need to be explored.
• Retroperitoneal Chronic Expanding Hematoma Mimicking Malignancy on FDG PET/CT.
  Haruki Narita; Junki Takenaka; Shiro Watanabe; Takashige Abe; Kohsuke Kudo
  Clinical nuclear medicine, 47, 9, e591-e593, 01 Sep. 2022, [International Magazine]
  English, Scientific journal, A 49-year-old Japanese man had a chief complaint of left hypochondrium pain, and a CT scan revealed a mass in the left retroperitoneal space. CT and MRI scans revealed a hemorrhagic component and surrounding fibrous tissues. FDG PET/CT images showed increased uptake in the peripheral rim of the mass, indicating a malignant tumor. The SUV max was 7.6. We surgically resected the mass. The pathological examination confirmed the diagnosis of chronic expanding hematoma. It is difficult to differentiate CEH from malignant tumors on imaging; this should be recognized as a diagnostic pitfall.
• AIによる肝臓セグメンテーションの性能評価と肝臓体積の経時的変化
  木村 理奈; 平田 健司; 常田 慧徳; 竹中 淳規; 渡邊 史郎; 阿保 大介; 工藤 與亮
  日本医学放射線学会秋季臨床大会抄録集, 59回, S403, S403, (公社)日本医学放射線学会, Sep. 2022
  Japanese
• Identification of patients with Graves' disease who benefit from high-dose radioactive iodine therapy.
  Shiro Watanabe; Shozo Okamoto; Kazumasa Akikawa; Noriyuki Miyamoto; Miyuki Okamura-Kawasaki; Yuko Uchiyama; Junki Takenaka; Takuya Toyonaga; Kenji Hirata; Kohsuke Kudo
  Annals of nuclear medicine, 16 Aug. 2022, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: Radioactive iodine (RAI) therapy is a useful treatment for Graves' disease (GD). Most RAI sessions administer ≤ 500 MBq of iodine (I)-131. Sometimes patients require repeated RAI, often for longer periods of remission. We investigated the characteristics of patients for whom high dose (mostly 1110 MBq of I-131) RAI was effective as RAI therapy for GD. METHODS: We retrospectively analyzed the cases of 79 patients who underwent RAI for GD in a multicenter setting. We divided the patients into two groups based on the I-131 dose administered: the low dose (LD) group who received ≤ 500 MBq (n = 44) and the high dose (HD) group who received > 500 MBq (n = 35). The therapeutic effect was defined as achieving remission and reaching the point of participating in thyroid hormone replacement therapy within 1 year after RAI. We compared the LD and HD groups' remission rates and conducted a multivariate logistic regression analysis of predictive factors for remission. In a simulation, using the formula for predicting the probability of remission obtained from the analysis results, we estimated how much the remission rate would change if the I-131 dose is increased from 500 to 1110 MBq. RESULTS: The mean ± standard deviation I-131 dose administered in the LD group was 480 ± 6 MBq, and that of the HD group was 1054 ± 265 MBq. Thirty-five patients (80%) in the LD group and 26 patients (74%) in the HD group achieved remission; this difference in the remission rate was not significant. The multivariate analysis results demonstrated that the absorbed dose and thyroid-stimulating antibody (TSAb) were independent predictors of remission. Seven patients (8.9%) showed an increased probability of remission from < 50% to > 50% when the higher RAI dose was applied (1110 MBq instead of 500 MBq). The thyroid volume and TSAb values in these patients were relatively large at 54.7 ± 34.2 mL and 1378.4 ± 586.3%, respectively. CONCLUSION: Although the overall remission rate was not significantly different between the patients who received high- or low-dose I-131, treatment with high-dose RAI may improve the probability of remission in patients with a massive thyroid volume and/or high-TSAb Graves' disease.
• バセドウ病に対するHigh dose I-131治療による治療効果の改善
  渡邊 史郎; 岡本 祥三; 秋川 和聖; 内山 裕子; 竹中 淳規; 平田 健司; 工藤 與亮
  核医学, 59, Suppl., S463, S463, (一社)日本核医学会, Aug. 2022
  Japanese
• Medical Radiation Exposure Reduction in PET via Super-Resolution Deep Learning Model
  Takaaki Yoshimura; Atsushi Hasegawa; Shoki Kogame; Keiichi Magota; Rina Kimura; Shiro Watanabe; Kenji Hirata; Hiroyuki Sugimori
  Diagnostics, 12, 4, 872, 872, MDPI AG, 31 Mar. 2022
  Scientific journal, In positron emission tomography (PET) imaging, image quality correlates with the injected [18F]-fluorodeoxyglucose (FDG) dose and acquisition time. If image quality improves from short-acquisition PET images via the super-resolution (SR) deep learning technique, it is possible to reduce the injected FDG dose. Therefore, the aim of this study was to clarify whether the SR deep learning technique could improve the image quality of the 50%-acquisition-time image to the level of that of the 100%-acquisition-time image. One-hundred-and-eight adult patients were enrolled in this retrospective observational study. The supervised data were divided into nine subsets for nested cross-validation. The mean peak signal-to-noise ratio and structural similarity in the SR-PET image were 31.3 dB and 0.931, respectively. The mean opinion scores of the 50% PET image, SR-PET image, and 100% PET image were 3.41, 3.96, and 4.23 for the lung level, 3.31, 3.80, and 4.27 for the liver level, and 3.08, 3.67, and 3.94 for the bowel level, respectively. Thus, the SR-PET image was more similar to the 100% PET image and subjectively improved the image quality, as compared to the 50% PET image. The use of the SR deep-learning technique can reduce the injected FDG dose and thus lower radiation exposure.
• 肺癌の再発・転移が疑われた後縦隔FDG陽性病変の診断に骨髄シンチグラフィが有用であった一例
  眞島 隆成; 竹中 淳規; 渡邊 史郎; 内山 裕子; 木村 理奈; 榊原 純; 平田 健司; 工藤 與亮
  北海道放射線医学雑誌, 2, 29, 33, (NPO)メディカルイメージラボ, Mar. 2022
  Japanese
• An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
  Anri Inaki; Tohru Shiga; Yoshito Tsushima; Megumi Jinguji; Hiroshi Wakabayashi; Daiki Kayano; Norihito Akatani; Takafumi Yamase; Yuji Kunita; Satoru Watanabe; Tomo Hiromasa; Hiroshi Mori; Kenji Hirata; Shiro Watanabe; Tetsuya Higuchi; Hiroyasu Tomonaga; Seigo Kinuya
  Annals of Nuclear Medicine, 36, 3, 267, 278, Springer Science and Business Media LLC, Mar. 2022, [Peer-reviewed]
  Scientific journal, Abstract
  
  Objective
  
  In this phase II study, we aimed to investigate the efficacy and safety of single-dose [¹³¹I]meta-iodobenzylguanidine (¹³¹I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL).
  
  Patients and methods
  
  This study was designed as an open-label, single-arm, multi-center, phase II clinical trial. The enrolled patients were administered 7.4 GBq of ¹³¹I-mIBG. Its efficacy was evaluated 12 and 24 weeks later, and its safety was monitored continuously until the end of the study. We evaluated the biochemical response rate as the primary endpoint using the one-sided exact binomial test based on the null hypothesis (≤ 5%).
  
  Results
  
  Seventeen patients were enrolled in this study, of which 16 were treated. The biochemical response rate (≥ 50% decrease in urinary catecholamines) was 23.5% (90% confidence interval: 8.5–46.1%, p = 0.009). The radiographic response rates, determined with CT/MRI according to the response evaluation criteria in solid tumors (RECIST) version 1.1 and ¹²³I-mIBG scintigraphy were 5.9% (0.3%–25.0%) and 29.4% (12.4%–52.2%), respectively. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) were gastrointestinal symptoms including nausea, appetite loss, and constipation, which were, together, observed in 15 of 16 patients. Hematologic TEAEs up to grade 3 were observed in 14 of 16 patients. No grade 4 or higher TEAEs were observed. All patients had experienced at least one TEAE, but no fatal or irreversible TEAEs were observed.
  
  Conclusion
  
  A single dose ¹³¹I-mIBG therapy was well tolerated by patients with PPGL, and statistically significantly reduced catecholamine levels compared to the threshold response rate, which may lead to an improved prognosis for these patients.
• 超解像深層学習を用いたPET検査における被ばく線量低減に向けた検討
  長谷川 淳; 吉村 高明; 孫田 恵一; 木村 理奈; 渡邊 史郎; 平田 健司
  日本放射線技術学会総会学術大会予稿集, 78回, 160, 160, (公社)日本放射線技術学会, Mar. 2022
  Japanese
• An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
  Anri Inaki; Tohru Shiga; Yoshito Tsushima; Megumi Jinguji; Hiroshi Wakabayashi; Daiki Kayano; Norihito Akatani; Takafumi Yamase; Yuji Kunita; Satoru Watanabe; Tomo Hiromasa; Hiroshi Mori; Kenji Hirata; Shiro Watanabe; Tetsuya Higuchi; Hiroyasu Tomonaga; Seigo Kinuya
  Annals of nuclear medicine, 36, 3, 267, 278, Mar. 2022, [Domestic magazines]
  English, Scientific journal, OBJECTIVE: In this phase II study, we aimed to investigate the efficacy and safety of single-dose [131I]meta-iodobenzylguanidine (131I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL). PATIENTS AND METHODS: This study was designed as an open-label, single-arm, multi-center, phase II clinical trial. The enrolled patients were administered 7.4 GBq of 131I-mIBG. Its efficacy was evaluated 12 and 24 weeks later, and its safety was monitored continuously until the end of the study. We evaluated the biochemical response rate as the primary endpoint using the one-sided exact binomial test based on the null hypothesis (≤ 5%). RESULTS: Seventeen patients were enrolled in this study, of which 16 were treated. The biochemical response rate (≥ 50% decrease in urinary catecholamines) was 23.5% (90% confidence interval: 8.5-46.1%, p = 0.009). The radiographic response rates, determined with CT/MRI according to the response evaluation criteria in solid tumors (RECIST) version 1.1 and 123I-mIBG scintigraphy were 5.9% (0.3%-25.0%) and 29.4% (12.4%-52.2%), respectively. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) were gastrointestinal symptoms including nausea, appetite loss, and constipation, which were, together, observed in 15 of 16 patients. Hematologic TEAEs up to grade 3 were observed in 14 of 16 patients. No grade 4 or higher TEAEs were observed. All patients had experienced at least one TEAE, but no fatal or irreversible TEAEs were observed. CONCLUSION: A single dose 131I-mIBG therapy was well tolerated by patients with PPGL, and statistically significantly reduced catecholamine levels compared to the threshold response rate, which may lead to an improved prognosis for these patients.
• Prediction of Amyloid-β Positivity Using QSM Images Based on Bootstrap Your Own Latent.
  Tsubasa Kunieda; Ren Togo; Noriko Nishioka; Yukie Shimizu; Shiro Watanabe; Kenji Hirata; Keisuke Maeda; Takahiro Ogawa 0001; Kohsuke Kudo; Miki Haseyama
  GCCE, 137, 138, IEEE, 2022
  International conference proceedings
• SiPM-PET/CT装置を用いた冠動脈18F-FDG集積の再現性評価
  渡邊 史郎; 納谷 昌直; 孫田 恵一; 真鍋 治; 新山 大樹; 平田 健司; 内山 裕子; 竹中 淳規; 工藤 與亮
  核医学, 58, Suppl., S210, S210, (一社)日本核医学会, Oct. 2021
  Japanese
• FDG-PET/CTのレポート上のSUVmaxを利用して解剖学用語を機械学習させる検討
  平田 健司; 渡邊 史郎; 内山 裕子; 竹中 淳規; 木村 理奈; 眞島 隆成; 孫田 恵一; 工藤 與亮
  核医学, 58, Suppl., S225, S225, (一社)日本核医学会, Oct. 2021
  Japanese
• Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma
  Yuko Uchiyama; Kenji Hirata; Shiro Watanabe; Shozo Okamoto; Tohru Shiga; Kazufumi Okada; Yoichi M. Ito; Kohsuke Kudo
  Annals of Nuclear Medicine, 35, 11, 1223, 1231, Springer Science and Business Media LLC, 11 Aug. 2021, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, BACKGROUND: Although patients with differentiated thyroid cancer (DTC) generally have a good prognosis, patients with a large metabolic tumor volume (MTV) on FDG-PET may experience poor clinical courses. We measured organ-based MTVs and tested its prognostic performance in comparison to conventional MTV (cMTV). METHODS: We retrospectively analyzed the cases of 280 patients who received their first I-131 therapy in 2003-2014 at our hospital and showed an FDG-avid metastatic lesion. We randomly divided the patients into training (n = 190) and validation (n = 90) datasets. We classified the MTVs as MTVneck-node, MTVdistant-node, MTVlung, MTVbone, and MTVother-organs and tested with/without dichotomization vis-à-vis overall survival (OS). Based on the estimated weighting coefficients of the organ-based MTVs, we propose a new index: the adjusted whole-body MTV (aMTV). Using the validation dataset, we compared the aMTV with cMTV for predicting OS. RESULTS: In a univariate analysis, MTVdistant-node and MTVother-organs were more strongly correlated with the OS than the dichotomized forms, whereas the dichotomized forms of MTVneck-node, MTVlung, and MTVbone were more strongly correlated with OS than the continuous variables. The aMTV was thus expressed as 0.69 × dic(MTVneck-node) + 0.02 × MTVdistant-node + 1.05 × dic(MTVlung) + 1.58 × dic(MTVbone) + 0.01 × MTVother-organs, where dic(x) represents 0 or 1 based on the optimized cut-off. In the model evaluation using the validation group, aMTV was a significant predictor of OS with a higher c-index (0.7676) than cMTV (0.7218). CONCLUSION: In DTC patients with FDG-avid metastasis before I-131 therapy, all organ-based MTVs were significant predictors of prognosis. As the aMTV outperformed the cMTV for predicting prognoses, we recommend measuring the MTV on an organ basis.
• 巨大乳腺腺筋上皮腫の1例 MRI所見を中心に
  竹中 淳規; 加藤 扶美; 富岡 伸元; 桑原 健; 渡邊 史郎; 坂井 亙; 鈴木 宏明; 高橋 將人; 南部 敏和; 工藤 與亮
  北海道放射線医学雑誌, 1, 12, 17, (NPO)メディカルイメージラボ, Mar. 2021
  Japanese
• Herpes zoster infection mimicking pelvic lymph node metastasis on FDG-PET/CT in a patient with cervical cancer.
  Kazutaka Harashima; Shiro Watanabe; Nanase Okazaki; Daisuke Endo; Yuko Uchiyama; Fumi Kato; Kenji Hirata; Kohsuke Kudo
  Asia Oceania journal of nuclear medicine & biology, 9, 2, 183, 187, 2021, [Peer-reviewed], [Corresponding author], [International Magazine]
  English, Although 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is an established method for the staging of malignancies, benign lesions (e.g, active inflammatory lesions) often show increased metabolic activity. Herpes zoster is the clinical manifestation of the activation and replication of dormant varicella-zoster virus (VZV) in individuals with decreased cell-mediated immunity. Although the diagnosis of herpes zoster is clinical, it is sometimes observed incidentally during imaging for another disease. We describe the case of a 67-year-old Japanese female patient diagnosed with cervical cancer in whom FDG-PET/CT revealed herpes zoster manifestations: hypermetabolic cutaneous lesions in the buttock and pelvic lymph node involvement. The resected lymph nodes showed no malignant lesions but revealed lymphoid follicle formation, probably related to viral infection. There has been no report comparing FDG-PET findings of lymph nodes with histologic findings; the present findings are compatible with a clinically VZV-induced inflammatory reaction in regional lymph nodes, which increased FDG accumulation. Active infection with VZV displays increased FDG uptake in regional lymph nodes and may lead to incorrect malignant disease management in oncology. Misdiagnoses can be avoided by a careful interpretation by experienced nuclear medicine physicians as well as proper clinical evaluation.
• A convolutional neural network-based system to classify patients using FDG PET/CT examinations
  Keisuke Kawauchi; Sho Furuya; Kenji Hirata; Chietsugu Katoh; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Tohru Shiga
  BMC Cancer, 20, 1, Springer Science and Business Media LLC, Dec. 2020, [Peer-reviewed]
  Scientific journal,
  
  As the number of PET/CT scanners increases and FDG PET/CT becomes a common imaging modality for oncology, the demands for automated detection systems on artificial intelligence (AI) to prevent human oversight and misdiagnosis are rapidly growing. We aimed to develop a convolutional neural network (CNN)-based system that can classify whole-body FDG PET as 1) benign, 2) malignant or 3) equivocal.
  
  
  
  
  This retrospective study investigated 3485 sequential patients with malignant or suspected malignant disease, who underwent whole-body FDG PET/CT at our institute. All the cases were classified into the 3 categories by a nuclear medicine physician. A residual network (ResNet)-based CNN architecture was built for classifying patients into the 3 categories. In addition, we performed a region-based analysis of CNN (head-and-neck, chest, abdomen, and pelvic region).
  
  
  
  
  There were 1280 (37%), 1450 (42%), and 755 (22%) patients classified as benign, malignant and equivocal, respectively. In the patient-based analysis, CNN predicted benign, malignant and equivocal images with 99.4, 99.4, and 87.5% accuracy, respectively. In region-based analysis, the prediction was correct with the probability of 97.3% (head-and-neck), 96.6% (chest), 92.8% (abdomen) and 99.6% (pelvic region), respectively.
  
  
  
  
  The CNN-based system reliably classified FDG PET images into 3 categories, indicating that it could be helpful for physicians as a double-checking system to prevent oversight and misdiagnosis.
  
  
  
• Biodistribution and internal radiation dosimetry of a novel probe for thymidine phosphorylase imaging, [123I]IIMU, in healthy volunteers.
  Shiro Watanabe; Ken-Ichi Nishijima; Shozo Okamoto; Keiichi Magota; Kenji Hirata; Takuya Toyonaga; Tohru Shiga; Yuji Kuge; Nagara Tamaki
  Annals of nuclear medicine, 34, 8, 595, 599, 02 May 2020, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, OBJECTIVE: We evaluated the radiation dosage, biodistribution, human safety, and tolerability of the injection of a single dose of [123I] 5-iodo-6-[(2-iminoimidazolidinyl)methyl]uracil (IIMU), a new radiotracer targeting thymidine phosphorylase (TP), in healthy volunteers. METHODS: Potential participants were tested at our hospital to confirm their eligibility. Two healthy male adults passed the screening tests. They were injected with 56 and 111 MBq of [123I]IIMU, respectively. Safety assessments were performed before and at 1, 3, 6, 9, 24, 48 h, and 1-week post-injection. Whole-body emission scans were conducted at 1, 3, 6, 24, and 48 h post-injection. Regions of interest were manually drawn to enclose the entire body at each time point, identifying high-uptake organs to obtain the time-activity curves. Urine and blood samples were collected at 1, 2, 3, 4, 5, 6, 9, 24, and 48 h post-injection. The radiation dose for each organ and the effective doses were estimated using OLINDA/EXM 1.1 software. RESULTS: No adverse events were observed as of the follow-up visit > 1-week post-injection. In both subjects, the highest uptake of [123I]IIMU occurred in the liver, with peak injected activity (%IA) values of 17.7% and 15.1%, respectively. The second highest uptake was in the thyroid (0.35% and 0.66% IA). The %IA decreased gradually toward the end of the study (48 h) in all organs except the liver and thyroid. By the end of the study, 52.5% and 51.5% of the injected activity of [123I]IIMU had been excreted via the subjects' renal systems. The estimated mean effective doses of [123I]IIMU were 9.19 μSv/MBq and 10.1 μSv/MBq, respectively. CONCLUSION: In this preliminary study, [123I]IIMU was safely administered to healthy adults, and its potential clinical use in TP imaging was revealed.
• Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
  Shiro Watanabe; Tetsuya Inoue; Shozo Okamoto; Keiichi Magota; Ayumi Takayanagi; Jun Sakakibara-Konishi; Norio Katoh; Kenji Hirata; Osamu Manabe; Takuya Toyonaga; Yuji Kuge; Hiroki Shirato; Nagara Tamaki; Tohru Shiga
  EJNMMI research, 9, 1, 104, 104, 04 Dec. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: We prospectively examined patients with pathologically proven NSCLC; all underwent FDG and FMISO PET/CT scans before SBRT. PET images were acquired using a whole-body time-of-flight PET-CT scanner with respiratory gating. We classified them into recurrent and non-recurrent groups based on their clinical follow-ups and compared the groups' tumor diameters and PET parameters (i.e., maximum of the standardized uptake value (SUVmax), metabolic tumor volume, tumor-to-muscle ratio, and tumor-to-blood ratio). We performed univariate analysis to evaluate the impact of the PET variables on the patients' progression-free survival (PFS). We divided the patients by thresholds of FDG SUVmax and FMISO SUVmax obtained from receiver operating characteristic analysis for assessment of recurrence rate and PFS. RESULTS: Thirty-two NSCLC patients (19 male and 13 females; median age, 83 years) were enrolled. All received SBRT. At the study endpoint, 23 patients (71.9%) were non-recurrent and nine patients (28.1%) had recurrent disease. Significant between-group differences were observed in tumor diameter and all the PET parameters, demonstrating that those were significant predictors of the recurrence in all patients. In the 22 patients with tumors > 2 cm, tumor diameter and FDG SUVmax were not significant predictors. Thirty-two patients were divided into three patterns from the thresholds of FDG SUVmax (6.81) and FMISO SUVmax (1.89); A, low FDG and low FMISO (n = 14); B, high FDG and low FMISO (n = 8); C, high FDG and high FMISO (n = 10). No pattern A patient experienced tumor recurrence, whereas two pattern B patients (25%) and seven pattern C patients (70%) exhibited recurrence. A Kaplan-Meier analysis of all patients revealed a significant difference in PFS between patterns A and B (p = 0.013) and between patterns A and C (p < 0.001). In the tumors > 2 cm patients, significant differences in PFS were demonstrated between pattern A and C patients (p = 0.002). CONCLUSION: The combination of FDG- and FMISO-PET can identify patients with a baseline risk of recurrence and indicate whether additional therapy might be performed to improve survival.
• MRI上、悪性が疑われた巨大乳腺腺筋上皮腫の1例
  竹中 淳規; 加藤 扶美; 坂井 亙; 木村 輔; 渡邉 史郎; 鈴木 純; 富岡 伸元; 桑原 健; 鈴木 宏明; 南部 敏和
  日本医学放射線学会秋季臨床大会抄録集, 55回, S472, S472, (公社)日本医学放射線学会, Sep. 2019
  Japanese
• Biodistribution and radiation dosimetry of the novel hypoxia PET probe [¹⁸F]DiFA and comparison with [¹⁸F]FMISO.
  Watanabe S; Shiga T; Hirata K; Magota K; Okamoto S; Toyonaga T; Higashikawa K; Yasui H; Kobayashi J; Nishijima KI; Iseki K; Matsumoto H; Kuge Y; Tamaki N
  EJNMMI research, 9, 1, 60, 60, Jul. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: To facilitate hypoxia imaging in a clinical setting, we developed 1-(2,2-dihydroxymethyl-3-[18F]-fluoropropyl)-2-nitroimidazole ([18F]DiFA) as a new tracer that targets tumor hypoxia with its lower lipophilicity and efficient radiosynthesis. Here, we evaluated the radiation dosage, biodistribution, human safety, tolerability, and early elimination after the injection of [18F]DiFA in healthy subjects, and we performed a preliminary clinical study of patients with malignant tumors in a comparison with [18F]fluoromisonidazole ([18F]FMISO). RESULTS: The single administration of [18F]DiFA in 8 healthy male adults caused neither adverse events nor abnormal clinical findings. Dynamic and sequential whole-body scans showed that [18F]DiFA was rapidly cleared from all of the organs via the hepatobiliary and urinary systems. The whole-body mean effective dose of [18F]DiFA estimated by using the medical internal radiation dose (MIRD) schema with organ level internal dose assessment/exponential modeling (OLINDA/EXM) computer software 1.1 was 14.4 ± 0.7 μSv/MBq. Among the organs, the urinary bladder received the largest absorbed dose (94.7 ± 13.6 μSv/MBq). The mean absorbed doses of the other organs were equal to or less than those from other hypoxia tracers. The excretion of radioactivity via the urinary system was very rapid, reaching 86.4 ± 7.1% of the administered dose. For the preliminary clinical study, seven patients were subjected to [18F]FMISO and [18F]DiFA positron emission tomography (PET) at 48-h intervals to compare the two tracers' diagnostic ability for tumor hypoxia. The results of the tumor hypoxia evaluation by [18F]DiFA PET at 1 h and 2 h were not significantly different from those obtained with [18F]FMISO PET at 4 h ([18F]DiFA at 1 h, p = 0.32; [18F]DiFA at 2 h, p = 0.08). Moreover, [18F]DiFA PET at both 1 h (k = 0.68) and 2 h (k = 1.00) showed better inter-observer reproducibility than [18F]FMISO PET at 4 h (k = 0.59). CONCLUSION: [18F]DiFA is well tolerated, and its radiation dose is comparable to those of other hypoxia tracers. [18F]DiFA is very rapidly cleared via the urinary system. [18F]DiFA PET generated comparable images to [18F]FMISO PET in hypoxia imaging with shorter waiting time, demonstrating the promising potential of [18F]DiFA PET for hypoxia imaging and for a multicenter trial.
• Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake.
  Osamu Manabe; Markus Kroenke; Tadao Aikawa; Atsuto Murayama; Masanao Naya; Atsuro Masuda; Noriko Oyama-Manabe; Kenji Hirata; Shiro Watanabe; Tohru Shiga; Chietsugu Katoh; Nagara Tamaki
  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 26, 3, 909, 918, Jun. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, OBJECTIVE: FDG PET/CT plays a significant role in the diagnosis of inflammatory heart diseases and cardiac tumors. We attempted to determine the optimal FDG uptake threshold for volume-based analyses and to evaluate the relationship between the myocardial physiological uptake volume in FDG PET and several clinical factors. METHODS: A total of 190 patients were retrospectively analyzed. The cardiac metabolic volume (CMV) was defined as a volume within the boundary determined by a threshold (SUVmean of blood pool × 1.5). RESULTS: The SUVmean of the blood pool measured in the descending aorta (DA) (r = 0.86, intraclass correlation coefficient [ICC] = 0.93, P < 0.0001) and that in the left ventricle (LV) cavity (r = 0.87, ICC = 0.90, P < 0.0001) showed high inter-operator reproducibility. However, the SUVmean in the LV cavity showed a significant correlation with the CMV (P = 0.0002, r = 0.26). The CMV in the patients who fasted < 18 hours were significantly higher (49.7  ±  73.2 vs. 18.0  ±  53.8 mL, P = 0.0013) compared to the patients with > 18-hour fasting. The multivariate analysis demonstrated that only the fasting period > 18 hours was independently associated with CMV = 0. CONCLUSION: Our findings revealed that the DA is suitable to decide the threshold for the volume-based analysis. The fasting time was significantly associated with the cardiac FDG uptake.
• A convolutional neural network-based system to prevent patient misidentification in FDG-PET examinations.
  Keisuke Kawauchi; Kenji Hirata; Chietsugu Katoh; Seiya Ichikawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Sho Furuya; Tohru Shiga
  Scientific reports, 9, 1, 7192, 7192, 10 May 2019, [Peer-reviewed], [International Magazine]
  English, Patient misidentification in imaging examinations has become a serious problem in clinical settings. Such misidentification could be prevented if patient characteristics such as sex, age, and body weight could be predicted based on an image of the patient, with an alert issued when a mismatch between the predicted and actual patient characteristic is detected. Here, we tested a simple convolutional neural network (CNN)-based system that predicts patient sex from FDG PET-CT images. This retrospective study included 6,462 consecutive patients who underwent whole-body FDG PET-CT at our institute. The CNN system was used for classifying these patients by sex. Seventy percent of the randomly selected images were used to train and validate the system; the remaining 30% were used for testing. The training process was repeated five times to calculate the system's accuracy. When images for the testing were given to the learned CNN model, the sex of 99% of the patients was correctly categorized. We then performed an image-masking simulation to investigate the body parts that are significant for patient classification. The image-masking simulation indicated the pelvic region as the most important feature for classification. Finally, we showed that the system was also able to predict age and body weight. Our findings demonstrate that a CNN-based system would be effective to predict the sex of patients, with or without age and body weight prediction, and thereby prevent patient misidentification in clinical settings.
• Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
  Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
  PloS one, 14, 2, e0213111, 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Hypoxia can induce radiation resistance and is an independent prognostic marker for outcome in head and neck cancer. As 18F-FMISO (FMISO), a hypoxia tracer for PET, is far less common than 18F-FDG (FDG) and two separate PET scans result in doubled cost and radiation exposure to the patient, we aimed to predict hypoxia from FDG PET with new techniques of voxel based analysis and texture analysis. METHODS: Thirty-eight patients with head-and-neck cancer underwent consecutive FDG and FMISO PET scans before any treatment. ROIs enclosing the primary cancer were compared in a voxel-by-voxel manner between FDG and FMISO PET. Tumour hypoxia was defined as the volume with a tumour-to-muscle ratio (TMR) > 1.25 in the FMISO PET and hypermetabolic volume was defined as >50% SUVmax in the FDG PET. The concordance rate was defined as percentage of voxels within the tumour which were both hypermetabolic and hypoxic. 38 different texture analysis (TA) parameters were computed based on the ROIs and correlated with presence of hypoxia. RESULTS: Within the hypoxic tumour regions, the FDG uptake was twice as high as in the non-hypoxic tumour regions (SUVmean 10.9 vs. 5.4; p<0.001). A moderate correlation between FDG and FMISO uptake was found by a voxel-by-voxel comparison (r = 0.664 p<0.001). The average concordance rate was 25% (± 22%). Entropy was the TA parameter showing the highest correlation with hypoxia (r = 0.524 p<0.001). CONCLUSION: FDG uptake was higher in hypoxic tumour regions than in non-hypoxic regions as expected by tumour biology. A moderate correlation between FDG and FMISO PET was found by voxel-based analysis. TA yielded similar results in FDG and FMISO PET. However, it may not be possible to predict tumour hypoxia even with the help of texture analysis.
• FMISO-PETによる心臓サルコイドーシス病変の評価
  古家 翔; 真鍋 治; 大平 洋; 納谷 昌直; 相川 忠夫; 小梁川 和宏; 渡邊 史郎; 小林 健太郎; 平田 健司; 志賀 哲; 真鍋 徳子
  核医学, 55, Suppl., S233, S233, (一社)日本核医学会, Nov. 2018, [Peer-reviewed]
  Japanese
• Strategy to develop convolutional neural network-based classifier for diagnosis of whole-body FDG PET images
  Keisuke Kawauchi; Kenji Hirata; Seiya Ichikawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Miki Haseyama; Takahiro Ogawa; Ren Togo; Tohru Shiga; Chietsugu Katoh
  Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), Jun. 2018, [Peer-reviewed]
  English, International conference proceedings
• Hypoxic volume evaluated by 18F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: preliminary analyses
  J. Sato; Y. Kitagawa; S. Watanabe; T. Asaka; N. Ohga; K. Hirata; T. Shiga; A. Satoh; N. Tamaki
  International Journal of Oral and Maxillofacial Surgery, 47, 5, 553, 560, Churchill Livingstone, 01 May 2018, [Peer-reviewed]
  English, Scientific journal
• Clinical possibility of baseline FDG-PET SUVmax as a prognostic factor in patients with head and neck non-Hodgkin's lymphoma: A preliminary study
  Kazuhito Yoshikawa; Makiko Onodera-Kyan; Yoshimasa Kitagawa; Akira Satoh; Jun Sato; Tetsuya Kitamura; Tohru Shiga; Shiro Watanabe; Nagara Tamaki
  Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 30, 4, 319, 323, Elsevier Ltd, 2018
  English, Scientific journal
• F-18-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma
  Jun Sato; Yoshimasa Kitagawa; Shiro Watanabe; Takuya Asaka; Noritaka Ohga; Kenji Hirata; Shozo Okamoto; Tohru Shiga; Masanobu Shindoh; Yuji Kuge; Nagara Tamaki
  ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 124, 3, 261, 270, Sep. 2017, [Peer-reviewed]
  English, Scientific journal
• Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors
  Yukiko Nishikawa; Koichi Yasuda; Shozo Okamoto; Yoichi M. Ito; Rikiya Onimaru; Tohru Shiga; Kazuhiko Tsuchiya; Shiro Watanabe; Wataru Takeuchi; Yuji Kuge; Hao Peng; Nagara Tamaki; Hiroki Shirato
  RADIATION ONCOLOGY, 12, 1, 148, Sep. 2017, [Peer-reviewed]
  English, Scientific journal
• Predicting hypoxia using texture parameters on CT in patients with non-small cell lung cancer
  Shiro Watanabe; Tohru Shiga; Kenji Hirata; Tetsuya Inoue; Shozo Okamoto; Takuya Toyonaga; Keiichi Magota; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
  JOURNAL OF NUCLEAR MEDICINE, 58, May 2017, [Peer-reviewed]
  English
• Convolutional neural network (CNN) of MRI and FDG-PET images may predict hypoxia in glioblastoma.
  Takuya Toyonaga; Tohru Shiga; Kenji Hirata; Shigeru Yamaguchi; Wataru Takeuchi; Kohsuke Kudo; Keiichi Magota; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Yuji Kuge; Nagara Tamaki
  JOURNAL OF NUCLEAR MEDICINE, 58, May 2017, [Peer-reviewed]
  English
• Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
  European journal of nuclear medicine and molecular imaging, 44, 4, 611, 619, Apr. 2017, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Metabolic activity and hypoxia are both important factors characterizing tumor aggressiveness. Here, we used F-18 fluoromisonidazole (FMISO) and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) to define metabolically active hypoxic volume, and investigate its clinical significance in relation to progression free survival (PFS) and overall survival (OS) in glioblastoma patients. EXPERIMENTAL DESIGN: Glioblastoma patients (n = 32) underwent FMISO PET, FDG PET, and magnetic resonance imaging (MRI) before surgical intervention. FDG and FMISO PET images were coregistered with gadolinium-enhanced T1-weighted MR images. Volume of interest (VOI) of gross tumor volume (GTV) was manually created to enclose the entire gadolinium-positive areas. The FMISO tumor-to-normal region ratio (TNR) and FDG TNR were calculated in a voxel-by-voxel manner. For calculating TNR, standardized uptake value (SUV) was divided by averaged SUV of normal references. Contralateral frontal and parietal cortices were used as the reference region for FDG, whereas the cerebellar cortex was used as the reference region for FMISO. FDG-positive was defined as the FDG TNR ≥1.0, and FMISO-positive was defined as FMISO TNR ≥1.3. Hypoxia volume (HV) was defined as the volume of FMISO-positive and metabolic tumor volume in hypoxia (hMTV) was the volume of FMISO/FDG double-positive. The total lesion glycolysis in hypoxia (hTLG) was hMTV × FDG SUVmean. The extent of resection (EOR) involving cytoreduction surgery was volumetric change based on planimetry methods using MRI. These factors were tested for correlation with patient prognosis. RESULTS: All tumor lesions were FMISO-positive and FDG-positive. Univariate analysis indicated that hMTV, hTLG, and EOR were significantly correlated with PFS (p = 0.007, p = 0.04, and p = 0.01, respectively) and that hMTV, hTLG, and EOR were also significantly correlated with OS (p = 0.0028, p = 0.037, and p = 0.014, respectively). In contrast, none of FDG TNR, FMISO TNR, GTV, HV, patients' age, or Karnofsky performance scale (KPS) was significantly correlated with PSF or OS. The hMTV and hTLG were found to be independent factors affecting PFS and OS on multivariate analysis. CONCLUSIONS: We introduced hMTV and hTLG using FDG and FMISO PET to define metabolically active hypoxic volume. Univariate and multivariate analyses demonstrated that both hMTV and hTLG are significant predictors for PFS and OS in glioblastoma patients.
• 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis.
  Osamu Manabe; Kenji Hirata; Okamoto Shozo; Tohru Shiga; Yuko Uchiyama; Kentaro Kobayashi; Shiro Watanabe; Takuya Toyonaga; Hisaya Kikuchi; Noriko Oyama-Manabe; Nagara Tamaki
  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 24, 1, 329, 331, Feb. 2017, [Peer-reviewed], [International Magazine]
  English, 18F-fluoromisonidazole (FMISO) is a positron emission tomography (PET) tracer that accumulates in hypoxic tissues. We here present a case of suspected cardiac sarcoidosis which was detected with increased FMISO uptake.
• The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy
  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Shiro Watanabe; Kenji Hirata; Ken-ichi Nishijima; Keiichi Magota; Katsuhiko Kasai; Rikiya Onimaru; Kazuhiko Tuchiya; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43, 12, 2147, 2154, Nov. 2016, [Peer-reviewed]
  English, Scientific journal
• The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Noriko Oyama-Manabe; Naoya Hattori; Yasuka Kikuchi; Kentaro Kobayashi; Takuya Toyonaga; Nagara Tamaki
  BMC cancer, 16, 635, 635, 15 Aug. 2016, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a benign lymphoid proliferation or malignant lymphoma in patients who have been treated with MTX. MTX withdrawal and observation for a short period should be considered in the initial management of patients who develop LPD while on MTX therapy. Here we evaluated the diagnostic accuracy and predictive value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for MTX-LPD. METHODS: We retrospectively investigated the cases of 15 patients clinically suspected of having MTX-LPD. A total of 324 anatomic regions (207 nodal and 117 extranodal regions) were assessed by (18)F-FDG PET/CT and by multi-detector row CT (MDCT). Each anatomic region was classified as either malignant or benign. The uptake of (18)F-FDG was assessed semi-quantitatively with the standardized uptake value maximum (SUVmax), the whole-body metabolic tumor volume (WBMTV), and the whole-body total lesion glycolysis (WBTLG) in order to investigate predictive factors of spontaneous regression after the withdrawal of MTX. RESULTS: MTX-LPD lesions were observed in 92/324 (28.4 %) regions. (18)F-FDG PET/CT showed 90.2 % sensitivity, 97.4 % specificity, and 95.4 % accuracy, values which were significantly higher than those of MDCT (59.8, 94.8, and 84.9 %, respectively. p < 0.002). After the withdrawal of MTX, 9/15 patients (60.0 %) achieved complete response (CR). The SUVmax, WBMTV and WBTLG values of the CR patients were 9.2 (range 2.8-47.1), 44.3 (range 0-362.6) ml, 181.8 (range 0-2180.9) ml, respectively, which were not significantly different from those of the non-CR patients: 10.6 (range 0-24.9), 15.7 (range 0-250.1) ml, and 97.4 (range 0-1052.1) ml. CONCLUSIONS: Although (18)F-FDG PET/CT was a useful tool to detect MTX-LPD lesions, none of the (18)F-FDG PET parameters before the withdrawal of MTX could be used to predict CR after the withdrawal of MTX.
• (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.
  Takuya Toyonaga; Kenji Hirata; Shigeru Yamaguchi; Kanako C Hatanaka; Sayaka Yuzawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Tohru Shiga; Shunsuke Terasaka; Hiroyuki Kobayashi; Yuji Kuge; Nagara Tamaki
  European journal of nuclear medicine and molecular imaging, 43, 8, 1469, 76, Jul. 2016, [Peer-reviewed], [International Magazine]
  English, PURPOSE: Tumor necrosis is one of the indicators of tumor aggressiveness. (18)F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoral necrosis can be detected by FMISO PET in brain tumors regardless of their histopathology. We applied FMISO PET to various types of brain tumors before tumor resection and evaluated the correlation between histopathological necrosis and FMISO uptake. METHODS: This study included 59 brain tumor patients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumors were divided into three groups: astrocytomas (group 1), neuroepithelial tumors except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumor was evaluated visually and semi-quantitatively using the tumor-to-normal cerebellum ratio (TNR). RESULTS: In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 (p < 0.00001) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 (p < 0.005) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 (p < 0.05) in group 3, respectively. Using a cut-off value of TNR = 1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7, 93.1, and 94.9 %, respectively. CONCLUSIONS: FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoral micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumor.
• Use of FDG-PET to detect a chronic odontogenic infection as a possible source of the brain abscess
  Jun Sato; Takeshi Kuroshima; Mayumi Wada; Akira Satoh; Shiro Watanabe; Shozo Okamoto; Tohru Shiga; Nagara Tamaki; Yoshimasa Kitagawa
  ODONTOLOGY, 104, 2, 239, 243, May 2016, [Peer-reviewed]
  English, Scientific journal
• Use of convolutional neural network as the first step of fully automated tumor detection on 11C-methionine brain PET
  Hirata Kenji; Takeuchi Wataru; Yamaguchi Shigeru; Kobayashi Hiroyuki; Terasaka Shunsuke; Toyonaga Takuya; Watanabe Shiro; Kobayashi Kentaro; Manabe Osamu; Kobashi Keiji; Shiga Tohru; Tamaki Nagara
  JOURNAL OF NUCLEAR MEDICINE, 57, 01 May 2016, [Peer-reviewed]
• Treatment monitoring with (18)F-FDG PET/CT in a patient with peritoneal tuberculosis.
  Shiro Watanabe; Osamu Manabe; Naoya Hattori; Florian C Gaertner; Kentaro Kobayashi; Atsuro Masuda; Nagara Tamaki
  European journal of nuclear medicine and molecular imaging, 41, 1, 184, 184, Jan. 2014, [Peer-reviewed], [International Magazine]
  English, Scientific journal

• Preliminary Exploration for Constructing an 18F-FDG PET/CT Report Generation System
  南和孝; 吉村高明; 平田健司; 吉村高明; 平田健司; 吉村高明; 平田健司; 吉村高明; 平田健司; 甲木晶枝; 植竹望; 唐明輝; 渡邊史郎; 工藤與亮; 唐明輝; 渡邊史郎; 工藤與亮; 渡邊史郎; 工藤與亮, 日本診療放射線技師会誌, 71, 10, 2024
• SRCNNを用いた短時間収集PET画像の画質改善モデルの開発と定量性評価
  遠藤大輝; 吉村高明; 唐明輝; 杉森博行; 長谷川淳; 小亀翔揮; 孫田惠一; 木村理奈; 渡邊史郎; 平田健司; 工藤與亮, 核医学(Web), 60, Supplement, 2023
• MIP類似アルゴリズムによるFDG-PET体表画像の有用性
  平田健司; 木村理奈; 唐明輝; 渡邊史郎; 竹中淳規; 若林直人; 杉森博行; 吉村高明; 工藤與亮; 平田健司; 木村理奈; 唐明輝; 渡邊史郎; 竹中淳規; 若林直人; 杉森博行; 吉村高明; 工藤與亮; 平田健司; 唐明輝; 渡邊史郎; 杉森博行; 吉村高明; 工藤與亮; 平田健司; 杉森博行; 吉村高明; 工藤與亮; 平田健司; 工藤與亮, 核医学(Web), 60, Supplement, 2023
• 超解像深層学習を用いたPET検査における被ばく線量低減に向けた検討
  長谷川淳; 吉村高明; 吉村高明; 孫田恵一; 木村理奈; 木村理奈; 渡邊史郎; 渡邊史郎; 平田健司; 平田健司, 日本放射線技術学会総会学術大会予稿集, 78th, 2022
• Role of 18F-FDG PET/CT in Evaluating MTX-Associated Lymphoproliferative Disorders
  真鍋治; 渡邊史郎; 小林健太郎; 平田健司, 画像診断, 38, 7, 689‐694, 25 May 2018
  Japanese
• 【関節リウマチの画像診断】 メトトレキサート関連疾患に対するFDG PET/CTの役割
  真鍋 治; 渡邊 史郎; 小林 健太郎; 平田 健司, 画像診断, 38, 7, 689, 694, May 2018
  (株)学研メディカル秀潤社, Japanese
• 新規低酸素トレーサー[18F]DiFAと[18F]FMISOの悪性腫瘍における低酸素集積の比較
  渡邊史郎; 平田健司; 小林健太郎; 安井博宣; 松本博樹; 久下裕司; 志賀哲, 核医学(Web), 55, Supplement, 2018
• FMISO-PETによる心臓サルコイドーシス病変の評価
  古家翔; 真鍋治; 大平洋; 納谷昌直; 相川忠夫; 小梁川和宏; 渡邊史郎; 小林健太郎; 平田健司; 志賀哲; 真鍋徳子, 核医学(Web), 55, Supplement, 2018
• Can F-18-fluoromisonidazole PET/CT Predict the Clinical Outcome for Stage I Non-small Cell Lung Cancer Treated By Stereotactic Body Radiation Therapy?
  T. Inoue; S. Watanabe; K. Harada; K. Yasuda; N. Katoh; S. Okamoto; T. Shiga; Y. Kuge; N. Tamaki; H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E466, E466, Oct. 2017
  English, Summary international conference
• TKI時代における転移再発甲状腺分化癌の放射線治療 放射性ヨード内用療法抵抗性の判断・適切なTKIへの橋渡し 核医学の立場から
  渡邊 史郎; 内山 裕子; 岡本 祥三; 志賀 哲, 日本内分泌・甲状腺外科学会雑誌, 34, Suppl.2, S224, S224, Oct. 2017
  日本内分泌外科学会・日本甲状腺外科学会, Japanese
• 放射性ヨード内用療法抵抗性の判断・適切なTKIへの橋渡し~核医学の立場から~
  渡邊史郎; 内山裕子; 岡本祥三; 志賀哲, 日本内分泌・甲状腺外科学会雑誌, 34, Supplement2, S224, 30 Sep. 2017
  Japanese
• CTテキスチャー解析による非小細胞肺癌の低酸素予測の可能性
  渡邊 史郎; 平田 健司; 岡本 祥三; 真鍋 治; 内山 裕子; 小林 健太郎; 豊永 拓哉; 井上 哲也; 孫田 恵一; 西嶋 剣一; 久下 裕司; 志賀 哲, 核医学, 54, Suppl., S170, S170, Sep. 2017
  (一社)日本核医学会, Japanese
• 巨大甲状腺腫を伴うバセドウ病に対するI-131 30mCi 1回投与に関する検討
  志賀 哲; 内山 裕子; 岡本 祥三; 平田 健司; 渡邊 史郎; 真鍋 治; 玉木 長良, 核医学, 54, Suppl., S176, S176, Sep. 2017
  (一社)日本核医学会, Japanese
• 18F-FDG PET/CT検査の11年間を振り返って
  伊藤 和夫; 鐘ヶ江 香久子; 渡邊 史郎; 真鍋 治; 細川 正夫, 核医学, 54, Suppl., S188, S188, Sep. 2017
  (一社)日本核医学会, Japanese
• Metavolによる全身FDG PET-CTのテクスチャー解析と甲状腺癌への応用
  平田 健司; 真鍋 治; 内山 裕子; 小林 健太郎; 渡邊 史郎; 豊永 拓哉; 志賀 哲, 核医学, 54, Suppl., S193, S193, Sep. 2017
  (一社)日本核医学会, Japanese
• F-18-Fluoromisonidazole positron emission tomography (FMISO-PET) may better reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma than F-fluoro-2-deoxyglucose (FDG)-PET: the third study
  Jun Sato; Yoshimasa Kitagawa; Shiro Watanabe; Shozo Okamoto; Noritaka Ohga; Takuya Asaka; Masaaki Miyakoshi; Kenji Hirata; Tohru Shiga; Yuji Kuge; Masanobu Shibndoh; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 58, May 2017
  English, Summary international conference
• FMISO-PET during intensity-modulated radiotherapy can predict more accurately than pre-therapeutic and post-therapeutic PET for head and neck cancer.
  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Shiro Watanabe; Keiichi Magota; Rikiya Onimaru; Kazuhiko Tsuchiya; Yuji Kuge; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 58, May 2017, [Peer-reviewed]
  English, Summary international conference
• First-in-Human Study of [F-18] DiFA, an improved PET probe for tumor hypoxia, in Six Healthy Volunteers.
  Shiro Watanabe; Shozo Okamoto; Kenji Hirata; Tohru Shiga; Takuya Toyonaga; Kentaro Kobayashi; Osamu Manabe; Yuko Uchiyama; Junya Katahata; Yamato Munakata; Keiichi Magota; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 58, May 2017, [Peer-reviewed]
  English, Summary international conference
• Semi-automated whole-body texture analysis may improve predictive performance of FDG PET-CT for patients with differentiated thyroid carcinoma
  Hirata Kenji; Shiga Tohru; Uchiyama Yuko; Watanabe Shiro; Toyonaga Takuya; Manabe Osamu; Kobayashi Kentaro; Kikuchi Hisaya; Magota Keiichi; Tamaki Nagara, JOURNAL OF NUCLEAR MEDICINE, 58, 01 May 2017, [Peer-reviewed]
• 18F-FDG PET/CTにより経過を追うことができた顆粒球肉腫の1例
  藤井 宝顕; 真鍋 治; 平田 健司; 渡邊 史郎; 真鍋 徳子; 工藤 與亮; 志賀 哲, 核医学, 54, 1, 652, 652, Feb. 2017
  (一社)日本核医学会, Japanese
• Relationships between preoperative FMISO and FDG PET parameters and the prognosis in patients with oral squamous cell carcinoma
  J. Sato; Y. Kitagawa; S. Watanabe; K. Hirata; S. Okamoto; N. Ohga; T. Asaka; M. Miyakoshi; T. Shiga; M. Shindoh; T. Nagara, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43, S56, S57, Oct. 2016
  English, Summary international conference
• Metabolic tumor volume in FDG PET/CT is a useful predictor for survival in patients with unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy
  S. Watanabe; M. Myoujin; K. Itoh; K. Hirata; O. Manabe; K. Kobayashi; Y. Onodera; K. Kanegae; H. Takahashi; M. Hosokawa; N. Tamaki, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43, S15, S16, Oct. 2016
  English, Summary international conference
• 神経膠腫の悪性度診断に11C-Methionine PETのtexture解析は有用か?
  小林 健太郎; 平田 健司; 山口 秀; 寺坂 俊介; 豊永 拓哉; 内山 裕子; 渡邊 史郎; 菊地 恒矢; 志賀 哲; 玉木 長良, 核医学, 53, Suppl., S257, S257, Oct. 2016
  (一社)日本核医学会, Japanese
• 転移を有する甲状腺分化癌において、FDG PETでのMTVとTLGは強い予後予測因子である SUVmaxとの比較
  内山 裕子; 平田 健司; 志賀 哲; 岡本 祥三; 真鍋 治; 小林 健太郎; 渡邊 史郎; 豊永 拓哉; 菊地 恒矢; 孫田 惠一; 玉木 長良, 核医学, 53, Suppl., S258, S258, Oct. 2016
  (一社)日本核医学会, Japanese
• 肺腺癌における原発巣のFDG集積と病理的な局所浸潤・リンパ節転移との関連について
  菊地 恒矢; 真鍋 治; 平田 健司; 岡本 祥三; 内山 裕子; 小林 健太郎; 渡邊 史郎; 豊永 拓哉; 志賀 哲; 玉木 長良, 核医学, 53, Suppl., S283, S283, Oct. 2016
  (一社)日本核医学会, Japanese
• 深層学習(deep learning)による脳腫瘍メチオニンPETの腫瘍・非腫瘍スライスの自動判定
  平田 健司; 竹内 渉; 山口 秀; 小林 浩之; 寺坂 俊介; 豊永 拓哉; 渡邊 史郎; 小林 健太郎; 小橋 啓司; 志賀 哲; 玉木 長良, 核医学, 53, Suppl., S309, S309, Oct. 2016
  (一社)日本核医学会, Japanese
• 非小細胞肺癌FMISO PET/CTにおける呼吸性移動距離と低酸素過小評価の検討
  渡邊 史郎; 平田 健司; 岡本 祥三; 志賀 哲; 井上 哲也; 孫田 惠一; 西嶋 剣一; 豊永 拓哉; 久下 裕司; 白土 博樹; 玉木 長良, 核医学, 53, Suppl., S317, S317, Oct. 2016
  (一社)日本核医学会, Japanese
• First-in-Human Study of a Novel Thymidine Phosphorylase Tracer [123I]IIMU in Healthy Volunteers - Preliminary Report
  Watanabe S; Hirata K; Shiga T; Toyonaga T; Okamoto S; Uchiyama Y; Munakata Y; Magota K; Shimizu Y; Nishijima K; Ohkura K; Kuge Y; Tamaki N, The 63nd Society of Nuclear Medicine and Molecular Imaging 2016, Jun. 2016
  English, Summary national conference
• Relationships between preoperative FMISO- and FDG-PET parameters and the prognosis in patients with oral squamous cell carcinoma
  Jun Sato; Yoshimasa Kitagawa; Shiro Watanabe; Kenji Hirata; Shozo Okamoto; Noritaka Ohga; Takuya Asaka; Masaaki Miyakoshi; Hironobu Hata; Tohru Shiga; Masanobu Shindoh; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 57, May 2016
  English, Summary international conference
• High Reproducibility of FMISO PET with high-definition semiconductor PET in patients with head and neck cancer.
  Tohru Shiga; Shozo Okamoto; Wataru Takeuchi; Atsuro Suzuki; Koichi Yasuda; Keiichi Magota; Shiro Watanabe; Kenji Hirata; Yuji Kuge; Keiji Kobashi; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 57, May 2016
  English, Summary international conference
• New SPECT scanner with semiconductor detectors enables quantitative dual tracer diagnostic imaging of CBF and Dopamine transporter imaging in patients with cognitive disorder.
  Takuya Toyonaga; Tohru Shiga; Atsuro Suzuki; Wataru Takeuchi; Shin Nakagawa; Kenji Hirata; Yuko Uchiyama; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Keiji Kobashi; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 57, May 2016
  English, Summary international conference
• 半導体SPECTを用いた¹²³I‐IFPと^99mTc‐ECDの2核種同時収集の検討
  豊永拓哉; 志賀哲; 鈴木敦郎; 竹内渉; 平田健司; 内山裕子; 真鍋治; 小林健太郎; 渡邊史郎; 小橋啓司; 玉木長良, JSMI Report, 9, 2, 112, 25 Apr. 2016
  Japanese
• 半導体SPECTを用いた¹²³I‐IFPと^99mTc‐ECDの2核種同時収集の検討
  豊永拓哉; 志賀哲; 鈴木敦郎; 竹内渉; 平田健司; 内山裕子; 真鍋治; 小林健太郎; 渡邊史郎; 小橋啓司; 玉木長良, JSMI Report, 9, 2, 168, 25 Apr. 2016
  Japanese
• 分子イメージングを用いた放射線治療
  安田耕一; 安田耕一; 岡本祥三; 西川由記子; 伊藤陽一; 志賀哲; 井上哲也; 森崇; 豊永拓哉; 鬼丸力也; 渡邊史郎; 土屋和彦; 竹内渉; 加藤徳雄; 加藤徳雄; 久下裕司; 玉木長良; 白土博樹; 白土博樹, JSMI Report, 9, 2, 83, 83, 25 Apr. 2016
  日本分子イメージング学会, Japanese
• チミジンホスホリラーゼイメージング製剤・[123I]IIMUの第1相試験：中間発表
  渡邊史郎; 平田健司; 志賀哲; 豊永拓哉; 岡本祥三; 内山裕子; 宗像大和; 孫田恵一; 志水陽一; 西嶋剣一; 大倉一枝; 久下裕司; 玉木長良, 第75回日本医学放射線学会総会, Apr. 2016
  Summary national conference
• TPイメージング製剤・[¹²³I]IIMUのFirst‐in‐Human Study:中間報告
  渡邊史郎; 平田健司; 志賀哲; 豊永拓哉; 岡本祥三; 内山裕子; 宗像大和; 孫田恵一; 志水陽一; 西嶋剣一; 大倉一枝; 久下裕司; 玉木長良, JSMI Report, 9, 2, 205, 205, Apr. 2016
  日本分子イメージング学会, Japanese
• Clinical application for molecular imaging(Therapy) 分子イメージングを用いた放射線治療
  安田 耕一; 岡本 祥三; 西川 由記子; 伊藤 陽一; 志賀 哲; 井上 哲也; 森 崇; 豊永 拓哉; 鬼丸 力也; 渡邊 史郎; 土屋 和彦; 竹内 渉; 加藤 徳雄; 久下 裕司; 玉木 長良; 白土 博樹, JSMI Report, 9, 2, 83, 83, Apr. 2016
  日本分子イメージング学会, Japanese
• 半導体SPECTを用いた123I-IFPと99mTc-ECDの2核種同時収集の検討
  豊永 拓哉; 志賀 哲; 鈴木 敦郎; 竹内 渉; 平田 健司; 内山 裕子; 真鍋 治; 小林 健太郎; 渡邊 史郎; 小橋 啓司; 玉木 長良, JSMI Report, 9, 2, 112, 112, Apr. 2016
  日本分子イメージング学会, Japanese
• TPイメージング製剤・[123I]IIMUのFirst-in-Human Study 中間報告
  渡邊 史郎; 平田 健司; 志賀 哲; 豊永 拓哉; 岡本 祥三; 内山 裕子; 宗像 大和; 孫田 恵一; 志水 陽一; 西嶋 剣一; 大倉 一枝; 久下 裕司; 玉木 長良, JSMI Report, 9, 2, 205, 205, Apr. 2016
  日本分子イメージング学会, Japanese
• Fanconi症候群に対して^99mTc‐DMSA腎静態シンチグラフィを施行した1例
  豊永拓哉; 服部直也; 真鍋治; 小林健太郎; 益田淳朗; 玉木長良; 渡邊史郎; 岡本孝之; 佐藤泰征; 山崎健史; 林麻子, Japanese Journal of Radiology, 34, Supplement, 7, 25 Feb. 2016
  Japanese
• Fanconi症候群に対して99mTc-DMSA腎静態シンチグラフィを施行した1例
  豊永 拓哉; 服部 直也; 真鍋 治; 小林 健太郎; 益田 淳朗; 玉木 長良; 渡邊 史郎; 岡本 孝之; 佐藤 泰征; 山崎 健史; 林 麻子, Japanese Journal of Radiology, 34, Suppl., 7, 7, Feb. 2016
  (公社)日本医学放射線学会, Japanese
• 中咽頭癌に合併し多発骨転移との鑑別が困難であった急性リンパ性白血病の一例
  渡邊 史郎; 真鍋 治; 平田 健司; 菊地 恒矢; 牧野 俊一; 豊永 拓哉; 小林 健太郎; 内山 裕子; 志賀 哲; 加納 里志; 玉木 長良, 核医学, 53, 1, 507, 507, Feb. 2016
  (一社)日本核医学会, Japanese
• 新規開発したチミジンホスホリラーゼ・イメージング製剤[123I]IIMUのPhase I study(中間報告) 抗がん剤治療効果予測を目指して
  渡邊 史郎; 平田 健司; 志賀 哲; 豊永 拓哉; 小林 健太郎; 真鍋 治; 岡本 祥三; 内山 裕子; 宗像 大和; 孫田 恵一; 西嶋 剣一; 久下 裕司; 玉木 長良, 核医学, 53, 1, 507, 507, Feb. 2016
  (一社)日本核医学会, Japanese
• 82Rbを用いた3次元収集PETでの心筋血流定量の試み
  真鍋 治; 吉永 敬一郎; 加藤 千恵次; 富山 勇輝; 渡邊 史郎; 菊地 恒矢; 玉木 長良, 核医学, 53, 1, 510, 510, Feb. 2016
  (一社)日本核医学会, Japanese
• 11C-hydroxyephedrine PETによる心筋交感神経終末機能及び心筋血流定量の試み
  真鍋 治; 富山 勇輝; 納屋 昌直; 小原 雅彦; 相川 忠夫; 渡邊 史郎; 菊地 恒矢; 加藤 千恵次; 玉木 長良, 核医学, 53, 1, 511, 511, Feb. 2016
  (一社)日本核医学会, Japanese
• texture analysisを用いた心サルコイドーシス病変に対するFDG集積の検討
  真鍋 治; 平田 健司; 納屋 昌直; 富山 勇輝; 小原 雅彦; 相川 忠夫; 渡邊 史郎; 菊地 恒矢; 玉木 長良, 核医学, 53, 1, 511, 511, Feb. 2016
  (一社)日本核医学会, Japanese
• FDG-PETを施行したIPNBの2症例
  菊地 恒矢; 真鍋 治; 渡邊 史郎; 平田 健司; 内山 裕子; 小林 健太郎; 豊永 拓哉; 牧野 俊一; 志賀 哲; 玉木 長良, 核医学, 53, 1, 512, 512, Feb. 2016
  (一社)日本核医学会, Japanese
• 非小細胞肺癌に対するFMISO PET/CTでの呼吸性移動は低酸素の過小評価と関連する
  渡邊 史郎, 核医学, 53, 1, 569, 569, Feb. 2016
  (一社)日本核医学会, Japanese
• 神経膠腫の悪性度診断に¹¹C‐Methionine PETのtexture解析は有用か?
  小林健太郎; 平田健司; 山口秀; 山口秀; 寺坂俊介; 豊永拓哉; 内山裕子; 渡邊史郎; 菊地恒矢; 志賀哲; 玉木長良, 核医学(Web), 53, Supplement, 1211(J‐STAGE), 2016
  Japanese
• 肺腺癌における原発巣のFDG集積と病理的な局所浸潤・リンパ節転移との関連について
  菊地恒矢; 真鍋治; 平田健司; 岡本祥三; 内山裕子; 小林健太郎; 渡邊史郎; 豊永拓哉; 志賀哲; 玉木長良, 核医学(Web), 53, Supplement, 1237(J‐STAGE), 2016
  Japanese
• 非小細胞肺癌FMISO PET/CTにおける呼吸性移動距離と低酸素過小評価の検討
  渡邊史郎; 平田健司; 岡本祥三; 志賀哲; 井上哲也; 孫田惠一; 西嶋剣一; 豊永和哉; 久下裕司; 白土博樹; 玉木長良, 核医学(Web), 53, Supplement, 1271(J‐STAGE), 2016
  Japanese
• ⁸²Rbを用いた3次元収集PETでの心筋血流定量の試み
  真鍋治; 吉永敬一郎; 加藤千恵次; 富山勇輝; 渡邊史郎; 菊地恒矢; 玉木長良, 核医学(Web), 53, 1, 510(J‐STAGE), 2016
  Japanese
• 新規開発したチミジンホスホリラーゼ・イメージング製剤[123I]IIMUのPhase I study(中間報告)~抗がん剤治療効果予測を目指して~
  渡邊史郎; 平田健司; 志賀哲; 豊永拓哉; 小林健太郎; 真鍋治; 岡本祥三; 内山裕子; 宗像大和; 孫田恵一; 西嶋剣一; 久下裕司; 玉木長良, 核医学(Web), 53, 1, 507‐508(J‐STAGE), 2016
  Japanese
• 中咽頭癌に合併し多発骨転移との鑑別が困難であった急性リンパ性白血病の一例
  渡邊史郎; 真鍋治; 平田健司; 菊地恒矢; 牧野俊一; 豊永拓哉; 小林健太郎; 内山裕子; 志賀哲; 加納里志; 玉木長良, 核医学(Web), 53, 1, 507(J‐STAGE), 2016
  Japanese
• ¹¹C‐hydroxyephedrine PETによる心筋交感神経終末機能及び心筋血流定量の試み
  真鍋治; 富山勇輝; 納屋昌直; 小原雅彦; 相川忠夫; 渡邊史郎; 菊地恒矢; 加藤千恵次; 玉木長良, 核医学(Web), 53, 1, 511(J‐STAGE), 2016
  Japanese
• texture analysisを用いた心サルコイドーシス病変に対するFDG集積の検討
  真鍋治; 平田健司; 納屋昌直; 富山勇輝; 小原雅彦; 相川忠夫; 渡邊史郎; 菊地恒矢; 玉木長良, 核医学(Web), 53, 1, 511(J‐STAGE), 2016
  Japanese
• 非小細胞肺癌に対するFMISO PET/CTでの呼吸性移動は低酸素の過小評価と関連する
  渡邊史郎, 核医学(Web), 53, 1, 569(J‐STAGE), 2016
  Japanese
• 転移を有する甲状腺分化癌において,FDG PETでのMTVとTLGは強い予後予測因子である―SUVmaxとの比較
  内山裕子; 平田健司; 志賀哲; 岡本祥三; 真鍋治; 小林健太郎; 渡邊史郎; 豊永拓哉; 菊地恒矢; 孫田惠一; 玉木長良, 核医学(Web), 53, Supplement, 1212(J‐STAGE), 2016
  Japanese
• 深層学習(deep learning)による脳腫瘍メチオニンPETの腫瘍・非腫瘍スライスの自動判定
  平田健司; 竹内渉; 山口秀; 小林浩之; 寺坂俊介; 豊永拓哉; 渡邊史郎; 小林健太郎; 小橋啓司; 志賀哲; 玉木長良, 核医学(Web), 53, Supplement, 1263(J‐STAGE), 2016
  Japanese
• FDG‐PETを施行したIPNBの2症例
  菊地恒矢; 真鍋治; 渡邊史郎; 平田健司; 内山裕子; 小林健太郎; 豊永拓哉; 牧野俊一; 志賀哲; 玉木長良, 核医学(Web), 53, 1, 512(J‐STAGE), 2016
  Japanese
• ADPKDののう胞感染の診断に¹⁸F‐FDG PET/CTが有用であった一例
  豊永拓哉; 真鍋治; 渡邊史郎; 小林健太郎; 内山裕子; 平田健司; 志賀哲; 玉木長良, 核医学, 52, 4, 382, 30 Nov. 2015
  Japanese
• ¹⁸F‐FDG PET/CT検査の新しい読影支援システム(Syngo.via,シーメンス社)の使用経験
  伊藤和夫; 鐘ケ江香久子; 渡邊史郎; 玉木長良, 核医学, 52, 4, 383, 30 Nov. 2015
  Japanese
• Respiration-gated F-18-fluoromisonidazole PET/CT for Stage I Non-Small Cell Lung Cancer Treated by Stereotactic Body Radiation Therapy
  T. Inoue; S. Okamoto; S. Watanabe; K. Yasuda; N. Katoh; K. Harada; R. Onimaru; T. Shiga; N. Tamaki; Y. Kuge; H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E390, E391, Nov. 2015
  English, Summary international conference
• The Voxel-based Analysis of FMISO-PET Image in Patients With Local Recurrence of Nasopharyngeal Carcinoma
  Y. Nishikawa; K. Yasuda; S. Okamoto; Y. M. Ito; T. Mori; R. Onimaru; T. Shiga; K. Tsuchiya; S. Watanabe; W. Takeuchi; N. Katoh; Y. Kuge; N. Tamaki; H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E337, E337, Nov. 2015
  English, Summary international conference
• ADPKDのうちの胸感染の診断に18F-FDG PET/CTが有用であった一例
  豊永 拓哉; 真鍋 治; 渡邊 史郎; 小林 健太郎; 内山 裕子; 平田 健司; 志賀 哲; 玉木 長良, 核医学, 52, 4, 382, 382, Nov. 2015
  (一社)日本核医学会, Japanese
• 18F-FDG PET/CT検査の新しい読影支援システム(Syngo.via、シーメンス社)の使用経験
  伊藤 和夫; 鐘ヶ江 香久子; 渡邊 史郎; 玉木 長良, 核医学, 52, 4, 383, 383, Nov. 2015
  (一社)日本核医学会, Japanese
• Respiratory-gated FMISO-PET/CT detects tumor hypoxia with higher sensitivity in non-small cell lung cancer
  S. Watanabe; S. Okamoto; T. Shiga; T. Inoue; K. Hirata; K. Magota; K. Nishijima; Y. Kuge; H. Shirato; N. Tamaki, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42, S61, S61, Oct. 2015
  English, Summary international conference
• 甲状腺分化癌の転移巣のFDG‐PETのSUVmaxは,I‐131治療後の予後を予測できる
  内山裕子; 岡本祥三; ガートナー フローリアン; 志賀哲; 平田健司; 真鍋治; 小林健太郎; 渡邊史郎; 豊永拓哉; 吉永恵一郎; 玉木長良, 核医学, 52, 3, 309, 30 Sep. 2015
  Japanese
• 乳癌の組織学的および免疫組織学的特性とFDG集積との関係
  伊藤和夫; 鈴木康弘; 渡邊史郎; 鐘ケ江香久子; 武内利直, 核医学, 52, 3, 289, 30 Sep. 2015
  Japanese
• 7年間2万例での悪性腫瘍別の平均SUV値:Reporting systemを用いた検討
  菊地恒矢; 平田健司; 真鍋治; 内山裕子; 小林健太郎; 渡邊史郎; 豊永拓哉; 牧野俊一; 富山勇輝; 志賀哲; 玉木長良, 核医学, 52, 3, 268, 30 Sep. 2015
  Japanese
• F‐18 FDG PET/CTにて偽陽性を示した内翻メッケル憩室の一例
  鐘ケ江香久子; 伊藤和夫; 渡邊史郎; 小池容史; 大橋宏和; 久須美貴哉; 澄川宗祐; 武内利直; 松本岳士; 高橋宏明, 核医学, 52, 3, 249, 30 Sep. 2015
  Japanese
• 乳癌骨転移診断:F‐18 FDG PET/CT検査と骨スキャンとの比較
  伊藤和夫; 鈴木康弘; 渡邊史郎; 鐘ケ江香久子, 核医学, 52, 3, 289, 30 Sep. 2015
  Japanese
• 非小細胞肺癌における呼吸同期を併用したFMISO‐PET/CTの低酸素定量評価についての検討
  渡邊史郎; 岡本祥三; 志賀哲; 井上哲也; 平田健司; 孫田恵一; 西嶋剣一; 西嶋剣一; 久下裕司; 白土博樹; 玉木長良, 核医学, 52, 3, 294, 294, Sep. 2015
  (一社)日本核医学会, Japanese
• F-18 FDG PET/CTにて偽陽性を示した内翻メッケル憩室の一例
  鐘ヶ江 香久子; 伊藤 和夫; 渡邊 史郎; 小池 容史; 大橋 宏和; 久須美 貴哉; 澄川 宗祐; 武内 利直; 松本 岳士; 高橋 宏明, 核医学, 52, 3, 249, 249, Sep. 2015
  (一社)日本核医学会, Japanese
• 7年間2万例での悪性腫瘍別の平均SUV値 Reporting systemを用いた検討
  菊地 恒矢; 平田 健司; 真鍋 治; 内山 裕子; 小林 健太郎; 渡邊 史郎; 豊永 拓哉; 牧野 俊一; 富山 勇輝; 志賀 哲; 玉木 長良, 核医学, 52, 3, 268, 268, Sep. 2015
  (一社)日本核医学会, Japanese
• 乳癌の組織学的および免疫組織学的特性とFDG集積との関係
  伊藤 和夫; 鈴木 康弘; 渡邊 史郎; 鐘ヶ江 香久子; 武内 利直, 核医学, 52, 3, 289, 289, Sep. 2015
  (一社)日本核医学会, Japanese
• 乳癌骨転移診断 F-18 FDG PET/CT検査と骨スキャンとの比較
  伊藤 和夫; 鈴木 康弘; 渡邊 史郎; 鐘ヶ江 香久子, 核医学, 52, 3, 289, 289, Sep. 2015
  (一社)日本核医学会, Japanese
• 非小細胞肺癌における呼吸同期を併用したFMISO-PET/CTの低酸素定量評価についての検討
  渡邊 史郎; 岡本 祥三; 志賀 哲; 井上 哲也; 平田 健司; 孫田 恵一; 西嶋 剣一; 久下 裕司; 白土 博樹; 玉木 長良, 核医学, 52, 3, 294, 294, Sep. 2015
  (一社)日本核医学会, Japanese
• 甲状腺分化癌の転移巣のFDG-PETのSUVmaxは、I-131治療後の予後を予測できる
  内山 裕子; 岡本 祥三; ガートナー・フローリアン; 志賀 哲; 平田 健司; 真鍋 治; 小林 健太郎; 渡邊 史郎; 豊永 拓哉; 吉永 恵一郎; 玉木 長良, 核医学, 52, 3, 309, 309, Sep. 2015
  (一社)日本核医学会, Japanese
• 当院における大腸癌に対する腹腔鏡下手術の現状と展望
  久須美貴哉; 坂下啓太; 三橋洋介; 澄川宗祐; 菊地健司; 吉川智宏; 佐々木邦明; 木ノ下義宏; 西田靖仙; 細川正夫; 穂刈格; 塚越洋元; 奥田博介; 渡邊史郎; 小野寺裕也; 伊藤和夫; 大内知之; 武内利直, 日本大腸こう門病学会雑誌, 68, 6, 455, Jun. 2015
  Japanese
• 当院における大腸癌に対する腹腔鏡下手術の現状と展望
  久須美 貴哉; 坂下 啓太; 三橋 洋介; 澄川 宗祐; 菊地 健司; 吉川 智宏; 佐々木 邦明; 木ノ下 義宏; 西田 靖仙; 細川 正夫; 穂刈 格; 塚越 洋元; 奥田 博介; 渡邊 史郎; 小野寺 裕也; 伊藤 和夫; 大内 知之; 武内 利直, 日本大腸肛門病学会雑誌, 68, 6, 455, 455, Jun. 2015
  (一社)日本大腸肛門病学会, Japanese
• Hypoxic volume evaluated by FMISO-PET reflects the expression of HIF-1 alpha and Ki-67 in oral squamous cell carcinoma
  Jun Sato; Yoshimasa Kitagawa; Shiro Watanabe; Shozo Okamoto; Noritaka Ohga; Takuya Asaka; Kenji Hirata; Tohru Shiga; Masanobu Shindoh; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 56, 3, May 2015
  English, Summary international conference
• Pretreatment FDG uptake in cervical lymph node was the most predictive factor of poor prognosis in locally advanced stage esophageal squamous cell carcinoma.
  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Kazuo Itoh; Miyako Myoujin; Hiroaki Takahashi; Masao Hosokawa; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 56, 3, May 2015
  English, Summary international conference
• Respiratory-gated FMISO-PET CT for the quantitative evaluation of hypoxia in non-small cell lung cancer.
  Watanabe Shiro; Okamoto Shozo; Shiga Tohru; Inoue Tetsuya; Hirata Kenji; Magota Keiichi; Nishijima Ken-ichi; Kuge Yuji; Shirato Hiroki; Tamaki Nagara, JOURNAL OF NUCLEAR MEDICINE, 56, 3, 01 May 2015, [Peer-reviewed]
• 高齢者大腸癌の当院の治療の推移と現況について
  久須美貴哉; 坂下啓太; 三橋洋介; 澄川宗祐; 鯉沼潤吉; 吉川智宏; 佐々木邦明; 木ノ下義宏; 西田靖仙; 細川正夫; 奥田博介; 穂刈格; 塚越洋元; 大内知之; 武内利直; 渡邊史郎; 小野寺裕也; 伊藤和夫, 日本大腸こう門病学会雑誌, 68, 5, 355, May 2015
  Japanese
• 高齢者大腸癌の当院の治療の推移と現況について
  久須美 貴哉; 坂下 啓太; 三橋 洋介; 澄川 宗祐; 鯉沼 潤吉; 吉川 智宏; 佐々木 邦明; 木ノ下 義宏; 西田 靖仙; 細川 正夫; 奥田 博介; 穂刈 格; 塚越 洋元; 大内 知之; 武内 利直; 渡邊 史郎; 小野寺 裕也; 伊藤 和夫, 日本大腸肛門病学会雑誌, 68, 5, 355, 355, May 2015
  (一社)日本大腸肛門病学会, Japanese
• 複数回の¹³¹I内用療法後に肺線維症をきたしたと思われる1例
  渡邊史郎; 岡本祥三; 志賀哲; 宗像大和; 潟端純也; 内山裕子; 吉永恵一郎; 玉木長良, 核医学, 51, 4, 413, 30 Nov. 2014
  Japanese
• 甲状腺分化癌肺転移に対する放射性ヨード内用療法後に重篤な汎血球減少を呈した1例
  岡本祥三; 志賀哲; 内山裕子; 渡邊史郎; 吉永恵一郎; 玉木長良, 核医学, 51, 4, 413, 414, 30 Nov. 2014
  Japanese
• Fanconi症候群に対して^99mTc‐DMSA腎静態シンチグラフィを施行した1例
  豊永拓哉; 服部直也; 真鍋治; 小林健太郎; 益田淳朗; 玉木長良; 渡邊史郎; 岡本孝之; 佐藤泰征; 山崎健史; 林麻子, 核医学, 51, 4, 420, 30 Nov. 2014
  Japanese
• 甲状腺分化癌肺転移に対する複数のI‐131内用療法後に肺線維症をきたした1例
  渡邊史郎; 岡本祥三; 志賀哲; 内山裕子; 玉木長良; 宗像大和; 片端純也; 吉永恵一郎, 北海道医学雑誌, 89, 2, 162, 01 Nov. 2014
  Japanese
• 甲状腺分化癌肺転移に対する複数のI-131内用療法後に肺線維症をきたした1例
  渡邊 史郎; 岡本 祥三; 志賀 哲; 内山 裕子; 玉木 長良; 宗像 大和; 潟端 純也; 吉永 恵一郎, 北海道医学雑誌, 89, 2, 162, 162, Nov. 2014
  北海道医学会, Japanese
• 複数回の131I内用療法後に肺線維症をきたしたと思われる1例
  渡邊 史郎; 岡本 祥三; 志賀 哲; 宗像 大和; 潟端 純也; 内山 裕子; 吉永 恵一郎; 玉木 長良, 核医学, 51, 4, 413, 413, Nov. 2014
  (一社)日本核医学会, Japanese
• 甲状腺分化癌肺転移に対する放射性ヨード内用療法後に重篤な汎血球減少を呈した1例
  岡本 祥三; 志賀 哲; 内山 裕子; 渡邊 史郎; 吉永 恵一郎; 玉木 長良, 核医学, 51, 4, 413, 414, Nov. 2014
  (一社)日本核医学会, Japanese
• Fanconi症候群に対して99mTc-DMSA腎静態シンチグラフィを施行した1例
  豊永 拓哉; 服部 直也; 真鍋 治; 小林 健太郎; 益田 淳朗; 玉木 長良; 渡邊 史郎; 岡本 孝之; 佐藤 泰征; 山崎 健史; 林 麻子, 核医学, 51, 4, 420, 420, Nov. 2014
  (一社)日本核医学会, Japanese
• Serial changes of hypoxia and glucose metabolism in head and neck cancer after Intensity Modulated Radiation Therapy
  S. Okamoto; T. Shiga; K. Yasuda; K. Magota; K. Kasai; S. Watanabe; Y. Kuge; H. Shirato; N. Tamaki, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S196, S196, Oct. 2014
  English, Summary international conference
• 皮膚悪性黒色腫における原発巣の糖代謝を用いたリンパ節転移の存在予測
  渡邊史郎; 真鍋治; 服部直也; 平田健司; 志賀哲; 玉木長良, 核医学, 51, 3, 304, 30 Sep. 2014
  Japanese
• バセドウ病に対する高投与量I‐131内用療法の治療効果と安全性
  内山裕子; 岡本祥三; 志賀哲; 渡邊史郎; 豊永拓哉; 吉永恵一郎; 玉木長良; 荒井博史; 孫田恵一, 核医学, 51, 3, 306, 30 Sep. 2014
  Japanese
• FMISO‐PETによる低酸素と糖代謝分布の相関についての検討
  渡邊史郎; 岡本祥三; 安田耕一; 志賀哲; 孫田恵一; 葛西克彦; 久下裕司; 白土博樹; 玉木長良, 核医学, 51, 3, 265, 265, 30 Sep. 2014
  (一社)日本核医学会, Japanese
• 甲状腺癌に対するI‐131AblationにおけるrhTSHの甲状腺ホルモン休薬と比較した治療時副作用軽減効果の検討
  豊永拓哉; 岡本祥三; 志賀哲; 内山裕子; 真鍋治; 小林健太郎; 益田淳朗; 渡邊史郎; 吉永恵一郎; 玉木長良, 核医学, 51, 3, 307, 30 Sep. 2014
  Japanese
• 転移病変を有する甲状腺分化癌におけるFDG‐PET陽性例でのSUVとI‐131内用療法後の予後に関する検討
  内山裕子; 岡本祥三; 志賀哲; 渡邊史郎; 豊永拓哉; 吉永恵一郎; 玉木長良; 荒井博史; 孫田恵一, 核医学, 51, 3, 325, 30 Sep. 2014
  Japanese
• Ablation目的にI‐131内用療法を予定された甲状腺癌患者の転移検索の臨床的重要性
  岡本祥三; 志賀哲; 内山裕子; 渡邊史郎; 豊永拓哉; 孫田恵一; 宗像大和; 荒井博史; 吉永恵一郎; 玉木長良, 核医学, 51, 3, 305, 30 Sep. 2014
  Japanese
• FMISO-PETによる低酸素と糖代謝分布の相関についての検討
  渡邊 史郎; 岡本 祥三; 安田 耕一; 志賀 哲; 孫田 恵一; 葛西 克彦; 久下 裕司; 白土 博樹; 玉木 長良, 核医学, 51, 3, 265, 265, Sep. 2014
  (一社)日本核医学会, Japanese
• 皮膚悪性黒色腫における原発巣の糖代謝を用いたリンパ節転移の存在予測
  渡邊 史郎; 真鍋 治; 服部 直也; 平田 健司; 志賀 哲; 玉木 長良, 核医学, 51, 3, 304, 304, Sep. 2014
  (一社)日本核医学会, Japanese
• Ablation目的にI-131内用療法を予定された甲状腺癌患者の転移検索の臨床的重要性
  岡本 祥三; 志賀 哲; 内山 裕子; 渡邊 史郎; 豊永 拓哉; 孫田 恵一; 宗像 大和; 荒井 博史; 吉永 恵一郎; 玉木 長良, 核医学, 51, 3, 305, 305, Sep. 2014
  (一社)日本核医学会, Japanese
• バセドウ病に対する高投与量I-131内用療法の治療効果と安全性
  内山 裕子; 岡本 祥三; 志賀 哲; 渡邊 史郎; 豊永 拓哉; 吉永 恵一郎; 玉木 長良; 荒井 博史; 孫田 恵一, 核医学, 51, 3, 306, 306, Sep. 2014
  (一社)日本核医学会, Japanese
• 甲状腺癌に対するI-131 AblationにおけるrhTSHの甲状腺ホルモン休薬と比較した治療時副作用軽減効果の検討
  豊永 拓哉; 岡本 祥三; 志賀 哲; 内山 裕子; 真鍋 治; 小林 健太郎; 益田 淳朗; 渡邊 史郎; 吉永 恵一郎; 玉木 長良, 核医学, 51, 3, 307, 307, Sep. 2014
  (一社)日本核医学会, Japanese
• 転移病変を有する甲状腺分化癌におけるFDG-PET陽性例でのSUVとI-131内用療法後の予後に関する検討
  内山 裕子; 岡本 祥三; 志賀 哲; 渡邊 史郎; 豊永 拓哉; 吉永 恵一郎; 玉木 長良; 荒井 博史; 孫田 恵一, 核医学, 51, 3, 325, 325, Sep. 2014
  (一社)日本核医学会, Japanese
• Value and limitation of 18F-FDG PET/CT for the assessment of methotrexate-associated lymphoproliferative disorder (MTX-LPD)
  Shiro Watanabe; Osamu Manabe; Naoya Hattori; Kenji Hirata; Noriko Oyama-Manabe; Tohru Shiga; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 55, May 2014
  English, Summary international conference
• High metabolic activity of the primary lesion in cutaneous malignant melanoma could predict for the presence of lymph node metastasis
  Shiro Watanabe; Osamu Manabe; Naoya Hattori; Kenji Hirata; Tohru Shiga; Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 55, May 2014
  English, Summary international conference
• Hypoxic information evaluated FMISO-PET was independent of glucose metabolic activity
  Watanabe Shiro; Okamoto Shozo; Shiga Tohru; Yasuda Koichi; Magota Keiichi; Kasai Katsuhiko; Kuge Yuji; Shirato Hiroki; Tamaki Nagara, JOURNAL OF NUCLEAR MEDICINE, 55, May 2014, [Peer-reviewed]
• 感染症に対するFDG‐PET/CTの有用性
  豊永拓哉; 小林健太郎; 益田淳朗; 服部直也; 真鍋治; 渡邊史郎; 玉木長良, 核医学, 51, 1, 29, 28 Feb. 2014
  Japanese
• 感染症に対するFDG-PET/CTの有用性
  豊永 拓哉; 小林 健太郎; 益田 淳朗; 服部 直也; 真鍋 治; 渡邊 史郎; 玉木 長良, 核医学, 51, 1, 29, 29, Feb. 2014
  (一社)日本核医学会, Japanese
• メトトレキサート関連リンパ腫におけるFDG‐PET/CTの有用性の検討
  渡邊史郎; 服部直也; 真鍋治; 志賀哲; 玉木長良, 核医学, 50, 3, 201, 30 Sep. 2013
  Japanese
• Whole body(WB)metabolic tumor volume(MTV)およびtotal lesion glycolysis(TLG)の計測環境の構築
  平田健司; 真鍋治; 小林健太郎; 渡邊史郎; 玉木長良; HUANG Sung‐Cheng, 核医学, 50, 3, 230, 30 Sep. 2013
  Japanese
• メトトレキサート関連リンパ腫におけるFDG-PET/CTの有用性の検討
  渡邊 史郎; 服部 直也; 真鍋 治; 志賀 哲; 玉木 長良, 核医学, 50, 3, S191, S191, Sep. 2013
  (一社)日本核医学会, Japanese
• Whole body(WB) metabolic tumor volume(MTV)およびtotal lesion glycolysis(TLG)の計測環境の構築
  平田 健司; 真鍋 治; 小林 健太郎; 渡邊 史郎; 玉木 長良; Huang Sung-Cheng, 核医学, 50, 3, S220, S220, Sep. 2013
  (一社)日本核医学会, Japanese
• FDG PET/CTによって病変範囲と治療効果を画像化できた皮下脂肪織炎様T細胞リンパ腫の一例
  渡邊史郎; 真鍋治; 石尾崇; 小林健太郎; 平田健司; 服部直也; 玉木長良; 白鳥聡一; 藤本勝也; 田中淳司, 核医学, 49, 4, 414, 30 Nov. 2012
  Japanese
• FDG PET/CTによって病変範囲と治療効果を画像化できた皮下脂肪織炎様T細胞リンパ腫の一例
  渡邊 史郎; 真鍋 治; 石尾 崇; 小林 健太郎; 平田 健司; 服部 直也; 玉木 長良; 白鳥 聡一; 藤本 勝也; 田中 淳司, 核医学, 49, 4, 414, 414, Nov. 2012
  (一社)日本核医学会, Japanese

• 医学総論, 2024年, 博士後期課程, 医学研究科
• 基本医学総論, 2024年, 修士課程, 医学院
• 基本医学総論, 2024年, 修士課程, 医学院
• 医理工連携機能画像診断学, 2024年, 修士課程, 医理工学院
• 医学総論, 2024年, 博士後期課程, 医学院
• 医学総論, 2024年, 博士後期課程, 医学院
• 臨床医学研究, 2024年, 博士後期課程, 医学院
• 画像診断学, 2024年, 学士課程, 医学部
• 核医学, 2024年, 学士課程, 医学部

• Development of a New Dosimetry Technique Using Air Dose Rates for Nuclear Medicine Theranostics
  Grants-in-Aid for Scientific Research
  01 Apr. 2024 - 31 Mar. 2027
  渡邊 史郎; 安井 博宣; 水野 雄貴
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 24K10753
• A new oral cancer treatment strategy based on hypoxia assessment
  Grants-in-Aid for Scientific Research
  01 Apr. 2022 - 31 Mar. 2025
  北川 善政; 竹内 康人; 渡邊 史郎; 平田 健司; 大賀 則孝; 佐藤 淳; 犬伏 正幸
  癌の治療抵抗性を評価することができれば、治療方針の決定や予後予測に役立つが、これまでに有用な評価手法が存在しなかった。そこで、われわれは癌細胞の治療抵抗性に関与するHIF-1/HREによる低酸素遺伝子応答のイメージングを試みた。
  低酸素遺伝子応答イメージング
  Na+/I-共輸送タンパク（NIS: sodium/iodine symporter）を利用して、癌細胞の低酸素遺伝子応答イメージングを行った。 具体的には、HIF-1/HREによる低酸素遺伝子応答によってNISを発現する癌細胞株を樹立し、PET（124/I-）あるいはSPECT（99mTcO4-）イメージングに成功した。HIF-1/HREによる低酸素遺伝子応答イメージングは、腫瘍の治療抵抗性を反映するイメージングと捉えることもできる。この新たなイメージング手法によって、既存の低酸素PETトレーサーの集積分布と腫瘍集積量（SUVmax）を、治療抵抗性という観点から評価することが可能になった。低酸素遺伝子応答イメージングを可能にする担癌マウス)を、3つの異なる酸素環境下（hyperoxia, normoxia, hypoxia）で飼育の後、18F-FMISO/99mTcO4-あるいは64Cu-ATSMを投与し、PET/SPECT同時収集イメージングを行った。3つの異なる酸素条件下で飼育したマウスで、デュアルトレーサーオートラジオグラフィーとPET/SPECT同時撮影を実施した。トレーサー蓄積量と腫瘍内分布を定量化した。
  クリニカルPET
  当科で根治手術を行ったOSCC患者の術前にFMISO-PET/CTとFDG-PET/CT検査を行った。画像の評価は当初はFDG-PET, FMISO-PETともStandardized UptakeValue(SUV)を測定して、腫瘍内のSUVの最高値: SUV maxを算出した。
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 23K24543
• ダイナミックPET検査における人工知能による動脈血放射能曲線の推定
  科学研究費助成事業
  01 Apr. 2022 - 31 Mar. 2025
  加藤 千恵次; 渡邊 史郎; 孫田 惠一
  日本学術振興会, 基盤研究(C), 北海道大学, 22K07658
• Novel strategies for the treatment of pral cancerbased on hypoxia assessment
  Grants-in-Aid for Scientific Research
  01 Apr. 2022 - 31 Mar. 2025
  北川 善政; 竹内 康人; 渡邊 史郎; 平田 健司; 大賀 則孝; 佐藤 淳; 犬伏 正幸
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (B), Hokkaido University, 22H03285
• Novel diagnostic strategy for refractory osteomyelitis of the jaw by hypoxia molecular imaging
  Grants-in-Aid for Scientific Research
  30 Jun. 2022 - 31 Mar. 2024
  北川 善政; 平田 健司; 渡邊 史郎; 佐藤 淳; 浅香 卓哉; 竹内 康人; 犬伏 正幸; 網塚 憲生
  Japan Society for the Promotion of Science, Grant-in-Aid for Challenging Research (Exploratory), Hokkaido University, 22K19608
• 適切な核医学治療の確立を目指した分化型甲状腺癌における分子生物学的特徴の解明
  科学研究費助成事業
  01 Apr. 2022 - 31 Mar. 2024
  渡邊 史郎
  日本学術振興会, 若手研究, 北海道大学, 22K15817
• 免疫治療における効果予測・評価のための低酸素イメージングバイオマーカーの確立
  科学研究費助成事業
  01 Apr. 2020 - 31 Mar. 2023
  渡邊 史郎
  低酸素と悪性腫瘍の関連にかかわる研究は基礎から臨床まで広く注目されており、生体での低酸素イメージング剤を用いた悪性腫瘍に対する治療の予後予測評価は多数の報告がある。多くはF-18 FMISOを用いた陽電子放出断層像（PET）であるが、いずれも低酸素が疑われる病変では予後や局所制御率が不良と報告されている。しかし、免疫チェックポイント阻害薬を用いた治療に関する予後予測や治療効果予測について、低酸素イメージングによる免疫治療の評価は行われていない。免疫チェックポイント治療は高価であり、またこれまでの抗がん剤とは異なる自己免疫メカニズムをもつ特異的な副作用を引き起こす。免疫関連有害事象として知られているが、まだ不明な点も多く、不必要なADLの低下や治療のコンプライアンスを低下させる恐れもある。
  非侵襲的な画像診断技術を用いて免疫治療の効果を事前に予測又は早期に判定することができれば、適切な患者選択、適切な投与回数・期間の決定、身体的負担の軽減、不要な副作用の回避、経済的な損失の抑制を実現できる可能性があり、その臨床的有用性や医療経済効果は極めて高いと言える。
  本研究ではF-18 FMISO PETを用いた非侵襲的な低酸素イメージングを用いた低酸素と治療効果の病態を明らかにするものである。FMISO PETは多くの施設では利用できず、広く研究を行うことは困難である。既存のFDG-PETやCTからFMISO PETの集積や低酸素を予測することでこれらの治療前後での低酸素による病態を一般的な施設で評価することが可能となる。
  日本学術振興会, 若手研究, 北海道大学, 20K16781
• Establishment of a new evaluation of tumor hypoxia using FDiFA-PET
  Grants-in-Aid for Scientific Research
  01 Apr. 2017 - 31 Mar. 2020
  Okamoto Shozo
  We performed FDiFA-PET on eight healthy subjects and confirmed the safety and comparable image quality for hypoxic evaluation in less time than a conventional FMISO-PET. This result suggests a reduced patient load and inconvenience in pre-treatment hypoxic evaluation.
  On the other hand, FMISO-PET confirmed that the prognosis of patients with accumulation in lesions was worse than that of patients with accumulation on FDG-PET alone. That result indicates the hypoxic PET is useful for predicting prognosis and necessitated new treatment strategies for these patients.
  Regarding pre-clinical study, animal stdies were also performed. It was suggested that high contrast images were obtained with FDiFA-PET in tumor-muscle ratio than FMISO-PET for several malignant tumors. That suggests FDiFA-PET can detect gypoxic area earlier than conventional FMISO-PET.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, 17K10428